

REFINITIV

DELTA REPORT

10-Q

GMRE - GLOBAL MEDICAL REIT INC.
10-Q - JUNE 30, 2024 COMPARED TO 10-Q - MARCH 31, 2024

The following comparison report has been automatically generated

TOTAL DELTAS	732
CHANGES	281
DELETIONS	153
ADDITIONS	298

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **March 31, June 30, 2024**

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____.

Commission file number: 001-37815

Global Medical REIT Inc.

(Exact name of registrant as specified in its charter)

Maryland	46-4757266
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
7373 Wisconsin Avenue, Suite 800	
Bethesda, MD	20814
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(202) 524-6851**

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol(s):	Name of each exchange on which registered:
Common Stock, par value \$0.001 per share	GMRE	NYSE
Series A Preferred Stock, par value \$0.001 per share	GMRE PrA	NYSE

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

The number of shares of the registrant's common stock outstanding at May 6, 2024 August 5, 2024 was 65,587,648

[Table of Contents](#)

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	
	Condensed Consolidated Balance Sheets – March 31, 2024 June 30, 2024 and December 31, 2023	3
	Condensed Consolidated Statements of Operations – Three and Six Months Ended March 31, 2024 June 30, 2024 and 2023	4
	Condensed Consolidated Statements of Comprehensive (Loss) Income (Loss) – Three and Six Months Ended March 31, 2024 June 30, 2024 and 2023	5
	Condensed Consolidated Statements of Equity – Three and Six Months Ended March 31, 2024 June 30, 2024 and 2023	6
	Condensed Consolidated Statements of Cash Flows – Three Six Months Ended March 31, 2024 June 30, 2024 and 2023	7 8
	Notes to the Unaudited Condensed Consolidated Financial Statements	8 9

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	23 24
---------	---	-------

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36 39
---------	--	-------

Item 4.	Controls and Procedures	36 39
---------	---	-------

PART II OTHER INFORMATION

Item 1.	Legal Proceedings	37 40
---------	-----------------------------------	-------

Item 1A.	Risk Factors	37 40
----------	------------------------------	-------

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37 40
---------	---	-------

Item 3.	Defaults Upon Senior Securities	37 40
---------	---	-------

Item 4.	Mine Safety Disclosures	37 40
---------	---	-------

Item 5.	Other Information	37 40
---------	-----------------------------------	-------

Item 6.	Exhibits	38 41
---------	--------------------------	-------

	Signatures	39 42
--	----------------------------	-------

[Table of Contents](#)

GLOBAL MEDICAL REIT INC.
Condensed Consolidated Balance Sheets
(unaudited and in thousands, except par values)

	As of		As of	
	March 31, 2024	December 31, 2023	June 30, 2024	December 31, 2023
Assets				
Investment in real estate:				
Land	\$ 164,315	\$ 164,315	\$ 162,391	\$ 164,315
Building	1,036,224	1,035,705	1,028,539	1,035,705
Site improvements	21,984	21,974	21,960	21,974
Tenant improvements	67,021	66,358	66,004	66,358
Acquired lease intangible assets	138,617	138,617	136,394	138,617
	1,428,161	1,426,969	1,415,288	1,426,969
Less: accumulated depreciation and amortization	(262,287)	(247,503)	(271,764)	(247,503)
Investment in real estate, net	1,165,874	1,179,466	1,143,524	1,179,466
Cash and cash equivalents	1,333	1,278	4,978	1,278
Restricted cash	6,473	5,446	2,840	5,446
Tenant receivables, net	7,743	6,762	8,073	6,762
Due from related parties	363	193	410	193
Escrow deposits	737	673	925	673
Deferred assets	27,995	27,132	28,360	27,132
Derivative asset	29,285	25,125	27,672	25,125
Goodwill	5,903	5,903	5,903	5,903
Other assets	17,874	15,722	18,530	15,722
Total assets	\$ 1,263,580	\$ 1,267,700	\$ 1,241,215	\$ 1,267,700
Liabilities and Equity				
Liabilities:				
Credit Facility, net of unamortized debt issuance costs of \$6,518 and \$7,067 at March 31, 2024 and December 31, 2023, respectively	\$ 592,082	\$ 585,333		
Notes payable, net of unamortized debt issuance costs of \$53 and \$66 at March 31, 2024 and December 31, 2023, respectively	25,682	25,899		
Credit Facility, net of unamortized debt issuance costs of \$5,968 and \$7,067 at June 30, 2024 and December 31, 2023, respectively			\$ 599,032	\$ 585,333
Notes payable, net of unamortized debt issuance costs of \$40 and \$66 at June 30, 2024 and December 31, 2023, respectively			14,638	25,899
Accounts payable and accrued expenses	10,520	12,781	11,962	12,781
Dividends payable	16,157	16,134	16,280	16,134
Security deposits	4,376	3,688	3,973	3,688
Other liabilities	12,952	12,770	12,809	12,770
Acquired lease intangible liability, net	4,713	5,281	4,149	5,281
Total liabilities	666,482	661,886	662,843	661,886
Commitments and Contingencies				

Equity:				
Preferred stock, \$0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at March 31, 2024 and December 31, 2023, respectively (liquidation preference of \$77,625 at March 31, 2024 and December 31, 2023, respectively)	74,959	74,959		
Common stock, \$0.001 par value, 500,000 shares authorized; 65,587 shares and 65,565 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	66	66		
Preferred stock, \$0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at June 30, 2024 and December 31, 2023, respectively (liquidation preference of \$77,625 at June 30, 2024 and December 31, 2023, respectively)			74,959	74,959
Common stock, \$0.001 par value, 500,000 shares authorized; 65,588 shares and 65,565 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively			66	66
Additional paid-in capital	722,623	722,418	722,627	722,418
Accumulated deficit	(251,963)	(238,984)	(268,885)	(238,984)
Accumulated other comprehensive income	29,285	25,125	27,672	25,125
Total Global Medical REIT Inc. stockholders' equity	574,970	583,584	556,439	583,584
Noncontrolling interest	22,128	22,230	21,933	22,230
Total equity	597,098	605,814	578,372	605,814
Total liabilities and equity	\$ 1,263,580	\$ 1,267,700	\$1,241,215	\$1,267,700

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-3-

[Table of Contents](#)

GLOBAL MEDICAL REIT INC.
Condensed Consolidated Statements of Operations
(unaudited and in thousands, except per share amounts)

	Three Months Ended March 31,	
	2024	2023
Revenue		
Rental revenue	\$ 35,069	\$ 36,199
Other income	49	31
Total revenue	35,118	36,230
Expenses		
General and administrative	4,446	3,804
Operating expenses	7,384	7,536
Depreciation expense	10,113	10,494
Amortization expense	3,971	4,395
Interest expense	6,890	8,271
Preacquisition expense	—	42
Total expenses	32,804	34,542
Income before gain on sale of investment property	2,314	1,688
Gain on sale of investment property	—	485
Net income	\$ 2,314	\$ 2,173
Less: Preferred stock dividends	(1,455)	(1,455)

Less: Net income attributable to noncontrolling interest	(65)	(45)		
Net income attributable to common stockholders	\$ 794	\$ 673		
Net income attributable to common stockholders per share – basic and diluted	\$ 0.01	\$ 0.01		
Weighted average shares outstanding – basic and diluted	65,573	65,525		
	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Revenue				
Rental revenue	\$ 34,214	\$ 36,317	\$ 69,283	\$ 72,517
Other income	27	34	77	64
Total revenue	34,241	36,351	69,360	72,581
Expenses				
General and administrative	4,589	4,462	9,035	8,266
Operating expenses	7,236	7,223	14,619	14,759
Depreciation expense	10,127	10,468	20,240	20,962
Amortization expense	3,866	4,337	7,838	8,732
Interest expense	6,992	8,468	13,883	16,739
Preacquisition expense	—	2	—	44
Total expenses	32,810	34,960	65,615	69,502
Income before (loss) gain on sale of investment properties	1,431	1,391	3,745	3,079
(Loss) gain on sale of investment properties	(3,383)	12,786	(3,383)	13,271
Net (loss) income	\$ (1,952)	\$ 14,177	\$ 362	\$ 16,350
Less: Preferred stock dividends	(1,455)	(1,455)	(2,911)	(2,911)
Less: Net loss (income) attributable to noncontrolling interest	260	(902)	195	(947)
Net (loss) income attributable to common stockholders	\$ (3,147)	\$ 11,820	\$ (2,354)	\$ 12,492
Net (loss) income attributable to common stockholders per share – basic and diluted	\$ (0.05)	\$ 0.18	\$ (0.04)	\$ 0.19
Weighted average shares outstanding – basic and diluted	65,588	65,544	65,580	65,534

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-4-

[Table of Contents](#)

GLOBAL MEDICAL REIT INC.
Condensed Consolidated Statements of Comprehensive (Loss) Income (Loss)
(unaudited and in thousands)

	Three Months Ended March 31,	
	2024	2023
Net income	\$ 2,314	\$ 2,173

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-5-

Table of Contents

GLOBAL MEDICAL REIT INC.
Condensed Consolidated Statements of Equity
(unaudited and in thousands, except per share amounts)

For the **Three** **Six** Months Ended **March 31, 2024** **June 30, 2024**:

REFINITIV CORPORATE DISCLOSURES | www.refinitiv.com | [Contact Us](#)

Change in fair value of interest rate swap agreements	—	—	—	—	—	—	4,160	4,160	—	4,160	—	—	—	—	—	2,5
Stock-based compensation expense	—	—	—	—	—	—	—	—	1,233	1,233	—	—	—	—	—	—
Dividends to common stockholders (\$0.21 per share)	—	—	—	—	—	(13,773)	—	(13,773)	—	(13,773)	—	—	—	—	—	—
Dividends to preferred stockholders (\$0.46875 per share)	—	—	—	—	—	(1,455)	—	(1,455)	—	(1,455)	—	—	—	—	—	—
Dividends to common stockholders (\$0.42 per share)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	(27,547)
Dividends to preferred stockholders (\$0.9375 per share)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	(2,911)
Dividends to noncontrolling interest	—	—	—	—	—	—	—	—	(1,195)	(1,195)	—	—	—	—	—	—
Balances, March 31, 2024	65,587	\$ 66	3,105	\$74,959	\$ 722,623	\$ (251,963)	\$ 29,285	\$ 574,970	\$ 22,128	\$597,098	—	—	—	—	—	—
Balances, June 30, 2024	—	—	—	—	—	—	—	—	—	—	65,588	\$ 66	3,105	\$74,959	\$ 722,627	\$ (268,885) \$ 27,6

For the Three Months Ended **March 31, 2023** **June 30, 2024**:

	Global																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																								
	Accumulated					Medical																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
	Additional					Other					REIT Inc.					Non-					Total					Additional					Other																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																										
	Common Stock		Preferred Stock		Paid-in Capital	Accumulated Deficit	Comprehensive Income	Stockholders' Equity	controlling Interest	Total Equity	Common Stock		Preferred Stock		Paid-in Capital	Accumulated Deficit	Comprehens																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																								
Shares	Amount	Shares	Amount	Shares							Amount	Shares	Amount																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												
Balances, December 31, 2022	65,518	\$ 66	3,105	\$74,959	\$ 721,991	\$ (198,706)	\$ 34,674	\$ 632,984	\$ 16,081	\$649,065																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															</

LTIP Units redeemed for common stock	12	—	—	—	122	—	—	122	(122)	—	1	—	—	—	4	—
Change in fair value of interest rate swap agreements	—	—	—	—	—	—	(7,264)	(7,264)	—	(7,264)	—	—	—	—	—	(1.6)
Stock-based compensation expense	—	—	—	—	—	—	—	—	688	688	—	—	—	—	—	—
Dividends to common stockholders (\$0.21 per share)	—	—	—	—	—	(13,761)	—	(13,761)	—	(13,761)	—	—	—	—	—	(13,774)
Dividends to preferred stockholders (\$0.46875 per share)	—	—	—	—	—	(1,455)	—	(1,455)	—	(1,455)	—	—	—	—	—	(1,456)
Dividends to noncontrolling interest	—	—	—	—	—	—	—	—	(971)	(971)	—	—	—	—	—	—
Balances, March 31, 2023	65,530	\$ 66	3,105	\$74,959	\$ 722,113	\$ (211,794)	\$ 27,410	\$ 612,754	\$ 15,721	\$628,475						
Balances, June 30, 2024											65,588	\$ 66	3,105	\$74,959	\$ 722,627	\$ (268,885) \$ 27.6

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-6-

[Table of Contents](#)

GLOBAL MEDICAL REIT INC.
Condensed Consolidated Statements of Equity - Continued
(unaudited and in thousands, except per share amounts)

For the Six Months Ended June 30, 2023:

	Global Medical REIT Inc.										
	Additional Paid-in Capital						Accumulated Deficit		Other Comprehensive Income		Global Medical REIT Inc. Stockholders' Equity
	Common Stock		Preferred Stock		Paid-in Capital	Accumulated Deficit	Comprehensive Income	Stockholders' Equity	Non-controlling Interest	Total Equity	
	Shares	Amount	Shares	Amount							
Balances, December 31, 2022	65,518	\$ 66	3,105	\$ 74,959	\$ 721,991	\$ (198,706)	\$ 34,674	\$ 632,984	\$ 16,081	\$ 649,065	
Net income	—	—	—	—	—	15,403	—	15,403	947	16,350	

LTIP Units redeemed for common stock	47	—	—	—	427	—	—	427	(427)	—
OP Units issued for a property acquisition	—	—	—	—	—	—	—	—	5,482	5,482
Change in fair value of interest rate swap agreements	—	—	—	—	—	—	1,185	1,185	—	1,185
Stock-based compensation expense	—	—	—	—	—	—	—	—	1,835	1,835
Dividends to common stockholders (\$0.42 per share)	—	—	—	—	—	(27,530)	—	(27,530)	—	(27,530)
Dividends to preferred stockholders (\$0.9375 per share)	—	—	—	—	—	(2,911)	—	(2,911)	—	(2,911)
Dividends to noncontrolling interest	—	—	—	—	—	—	—	—	(2,084)	(2,084)
Balances, June 30, 2023	65,565	\$ 66	3,105	\$ 74,959	\$ 722,418	\$ (213,744)	\$ 35,859	\$ 619,558	\$ 21,834	\$ 641,392

For the Three Months Ended June 30, 2023:

								Global		
								Medical		
								Other	REIT Inc.	Non-
	Common Stock		Preferred Stock		Paid-in	Accumulated	Comprehensive	Stockholders'	controlling	Total
	Shares	Amount	Shares	Amount	Capital	Deficit	Income	Equity	Interest	Equity
Balances, March 31, 2023	65,530	\$ 66	3,105	\$ 74,959	\$ 722,113	\$ (211,794)	\$ 27,410	\$ 612,754	\$ 15,721	\$ 628,475
Net income	—	—	—	—	—	13,275	—	13,275	902	14,177
LTIP Units redeemed for common stock	35	—	—	—	305	—	—	305	(305)	—
OP Units issued for a property acquisition	—	—	—	—	—	—	—	—	5,482	5,482
Change in fair value of interest rate swap agreements	—	—	—	—	—	—	8,449	8,449	—	8,449
Stock-based compensation expense	—	—	—	—	—	—	—	—	1,147	1,147
Dividends to common stockholders (\$0.21 per share)	—	—	—	—	—	(13,769)	—	(13,769)	—	(13,769)
Dividends to preferred stockholders (\$0.46875 per share)	—	—	—	—	—	(1,456)	—	(1,456)	—	(1,456)
Dividends to noncontrolling interest	—	—	—	—	—	—	—	—	(1,113)	(1,113)
Balances, June 30, 2023	65,565	\$ 66	3,105	\$ 74,959	\$ 722,418	\$ (213,744)	\$ 35,859	\$ 619,558	\$ 21,834	\$ 641,392

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

[Table of Contents](#)

GLOBAL MEDICAL REIT INC.
Condensed Consolidated Statements of Cash Flows
(unaudited and in thousands)

	Three Months Ended March 31,	
	2024	2023
Operating activities		

Net income	\$	2,314	\$	2,173
Adjustments to reconcile net income to net cash provided by operating activities:				
Depreciation expense		10,113		10,494
Amortization of acquired lease intangible assets		3,863		4,373
Amortization of above market leases, net		251		291
Amortization of debt issuance costs and other		562		601
Stock-based compensation expense		1,233		688
Capitalized preacquisition and other costs charged to expense		34		15
Gain on sale of investment property		—		(485)
Other		169		—
Changes in operating assets and liabilities:				
Tenant receivables		(981)		638
Deferred assets		(863)		(811)
Other assets and liabilities		(1,033)		(210)
Accounts payable and accrued expenses		(2,057)		(1,223)
Security deposits		688		(773)
Net cash provided by operating activities		<u>14,293</u>		<u>15,771</u>
Investing activities				
Net proceeds from sale of investment property		—		4,175
Escrow deposits for purchase of properties		—		(153)
Advances made to related parties		(170)		(121)
Capital expenditures on existing real estate investments		(2,004)		(809)
Leasing commissions		(542)		—
Net cash (used in) provided by investing activities		<u>(2,716)</u>		<u>3,092</u>
Financing activities				
Escrow deposits required by third party lenders		(64)		(639)
Repayment of notes payable		(230)		(344)
Proceeds from Credit Facility		14,000		12,600
Repayment of Credit Facility		(7,800)		(14,800)
Dividends paid to common stockholders, and OP Unit and LTIP Unit holders		(14,946)		(14,699)
Dividends paid to preferred stockholders		(1,455)		(1,455)
Net cash used in financing activities		<u>(10,495)</u>		<u>(19,337)</u>
Net increase (decrease) in cash and cash equivalents and restricted cash		<u>1,082</u>		<u>(474)</u>
Cash and cash equivalents and restricted cash—beginning of period		<u>6,724</u>		<u>14,455</u>
Cash and cash equivalents and restricted cash—end of period	\$	<u>7,806</u>	\$	<u>13,981</u>
Supplemental cash flow information:				
Cash payments for interest	\$	6,407	\$	8,139
Noncash financing and investing activities:				
Accrued dividends payable	\$	16,156	\$	15,854
Interest rate swap agreements fair value change recognized in other comprehensive income (loss)	\$	(4,160)	\$	7,264
LTIP Units redeemed for common stock	\$	205	\$	122
Accrued capital expenditures and leasing commissions included in accounts payable and accrued expenses	\$	1,946	\$	778
Six Months Ended June 30,				
		2024		2023
Operating activities				
Net income	\$	362	\$	16,350
Adjustments to reconcile net income to net cash provided by operating activities:				
Depreciation expense		20,240		20,962
Amortization of acquired lease intangible assets		7,629		8,679

Amortization of above market leases, net	500	578
Amortization of debt issuance costs and other	1,125	1,202
Stock-based compensation expense	2,552	1,835
Capitalized preacquisition and other costs charged to expense	82	76
Reserve for uncollectible accounts, net	822	—
Loss (gain) on sale of investment properties	3,383	(13,271)
Other	202	121
Changes in operating assets and liabilities:		
Tenant receivables	(2,133)	659
Deferred assets	(1,265)	(1,731)
Other assets and liabilities	(291)	(224)
Accounts payable and accrued expenses	(272)	(339)
Security deposits	285	(1,248)
Net cash provided by operating activities	<u>33,221</u>	<u>33,649</u>
Investing activities		
Purchase of land, buildings, and other tangible and intangible assets and liabilities	—	(442)
Net proceeds from sale of investment properties	7,537	68,403
Escrow deposits for purchase of properties	(500)	—
Advances made to related parties	(217)	(191)
Capital expenditures on existing real estate investments	(5,206)	(2,333)
Leasing commissions	(2,545)	(371)
Net cash (used in) provided by investing activities	<u>(931)</u>	<u>65,066</u>
Financing activities		
Escrow deposits required by third party lenders	248	(902)
Repayment of notes payable	(11,287)	(628)
Proceeds from Credit Facility	38,500	24,600
Repayment of Credit Facility	(25,900)	(94,157)
Dividends paid to common stockholders, and OP Unit and LTIP Unit holders	(29,846)	(29,387)
Dividends paid to preferred stockholders	(2,911)	(2,911)
Net cash used in financing activities	<u>(31,196)</u>	<u>(103,385)</u>
Net increase (decrease) in cash and cash equivalents and restricted cash	1,094	(4,670)
Cash and cash equivalents and restricted cash—beginning of period	6,724	14,455
Cash and cash equivalents and restricted cash—end of period	<u>\$ 7,818</u>	<u>\$ 9,785</u>
Supplemental cash flow information:		
Cash payments for interest	\$ 12,583	\$ 16,286
Noncash financing and investing activities:		
Accrued dividends payable	\$ 16,280	\$ 16,048
Interest rate swap agreements fair value change recognized in other comprehensive (loss) income	\$ 2,547	\$ 1,185
LTIP Units redeemed for common stock	\$ 209	\$ 427
Accrued capital expenditures and leasing commissions included in accounts payable and accrued expenses	\$ 1,442	\$ 2,912
OP Units issued for a property acquisition	\$ —	\$ 5,482
Proceeds from sale of an investment property held in escrow	\$ —	\$ 990
Recognition of lease liability related to right of use asset	\$ —	\$ 4,634

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

GLOBAL MEDICAL REIT INC.**Notes to the Unaudited Condensed Consolidated Financial Statements**
(dollars in thousands, except per share amounts or as otherwise indicated)**Note 1 – Organization**

Global Medical REIT Inc. (the “Company”) is a Maryland corporation and internally managed real estate investment trust (“REIT”) that owns and acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. The Company holds its facilities and conducts its operations through a Delaware limited partnership subsidiary, Global Medical REIT L.P. (the “Operating Partnership”). The Company serves as the sole general partner of the Operating Partnership through a wholly owned subsidiary of the Company, Global Medical REIT GP LLC, a Delaware limited liability company. As of March 31, 2024 June 30, 2024, the Company was the 92.44% 92.36% limited partner of the Operating Partnership, with an aggregate of 7.56% 7.64% of the Operating Partnership owned by holders of long-term incentive plan units (“LTIP Units”) and third-party limited partners who contributed properties or services to the Operating Partnership in exchange for common limited partnership units (“OP Units”).

Note 2 – Summary of Significant Accounting Policies**Basis of presentation**

The accompanying condensed consolidated financial statements are unaudited and include the accounts of the Company, including the Operating Partnership and its wholly owned subsidiaries. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures required for annual consolidated financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, the accompanying condensed consolidated financial statements do not include all the information and footnotes required by GAAP for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023. In the opinion of management, all adjustments of a normal and recurring nature necessary for a fair presentation of the condensed consolidated financial statements for the interim periods have been made.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The Company presents the portion of any equity it does not own but controls (and thus consolidates) as noncontrolling interest. Noncontrolling interest in the Company includes the LTIP Units that have been granted to directors, officers and affiliates of the Company and the OP Units held by third parties. Refer to Note 5 – “Equity” and Note 7 – “Stock-Based Compensation” for additional information regarding the OP Units and LTIP Units.

The Company classifies noncontrolling interest as a component of consolidated equity on its Condensed Consolidated Balance Sheets, separate from the Company's total equity. The Company's net income or loss is allocated to noncontrolling interests based on the respective ownership or voting percentage in the Operating Partnership associated with such noncontrolling interests and is removed from consolidated income or loss on the Condensed Consolidated Statements of Operations in order to derive net income or loss attributable to common stockholders. The noncontrolling ownership percentage is calculated by dividing the aggregate number of LTIP Units and OP Units by the total number of units and shares outstanding.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Actual results could differ from those estimates.

Investment in Real Estate

The Company determines when an acquisition meets the definition of a business or alternatively should be accounted for as an asset acquisition in accordance with Accounting Standard Codification (“ASC”) Topic 805 “Business Combinations” (“ASC Topic 805”), which requires that, when substantially all of the fair value of an acquisition is concentrated in a single identifiable asset or a

group of similar identifiable assets, the asset or group of similar identifiable assets does not meet the definition of a business and therefore is required to be accounted for as an asset acquisition. Transaction costs are capitalized for asset acquisitions and expensed as incurred for business combinations.

For asset acquisitions that are "owner occupied" (meaning that the seller either is the tenant or controls the tenant), the purchase price, including capitalized acquisition costs, will be allocated to land and building based on their relative fair values with no value allocated to intangible assets or liabilities. For asset acquisitions where there is a lease in place but that are not "owner occupied," the Company will allocate the purchase price to tangible assets and any intangible assets acquired or liabilities assumed based on their relative fair values. Fair value is determined based upon the guidance of ASC Topic 820, "Fair Value Measurements and Disclosures," and generally are determined using Level 2 inputs, such as rent comparables, sales comparables, and broker indications. Although Level 3 inputs are utilized, they are minor in comparison to the Level 2 data used for the primary assumptions. The determination of fair value involves the use of significant judgment and estimates. We make estimates to determine the fair value of the tangible and intangible assets acquired and liabilities assumed using information obtained from multiple sources, including preacquisition due diligence, and we routinely utilize the assistance of a third-party appraiser.

Revenue Recognition

The Company's operations primarily consist of rental revenue earned from tenants under leasing arrangements which provide for minimum rent and escalations. The leases have been accounted for as operating leases. For operating leases with contingent rental escalators, revenue is recorded based on the contractual cash rental payments due during the period. Revenue from leases with fixed annual rental escalators are recognized on a straight-line basis over the initial lease term, subject to a collectability assessment, with the difference between the contractual rental receipts and the straight-line amounts recorded as a "deferred rent receivable." Additionally, the Company recognizes as a component of rental revenue "expense recoveries" revenue, which represents revenue recognized related to tenant reimbursement of real estate taxes, insurance, and certain other operating expenses ("tenant reimbursements"). The Company recognizes these reimbursements and related expenses on a gross basis in its Condensed Consolidated Statements of Operations.

Cash and Cash Equivalents and Restricted Cash

The Company considers all demand deposits, cashier's checks, money market accounts, and certificates of deposit with a maturity of three months or less to be cash equivalents. Amounts included in restricted cash represent certain security deposits received from tenants at the inception of their leases and funds held by the Company related to certain tenant reimbursements. The following table provides a reconciliation of the Company's cash and cash equivalents and restricted cash that sums to the total of those amounts at the end of the periods presented on the Company's accompanying Condensed Consolidated Statements of Cash Flows:

	As of March 31,		As of June 30,	
	2024	2023	2024	2023
Cash and cash equivalents	\$ 1,333	\$ 4,603	\$ 4,978	\$ 2,460
Restricted cash	6,473	9,378	2,840	7,325
Total cash and cash equivalents and restricted cash	\$ 7,806	\$ 13,981	\$ 7,818	\$ 9,785

Tenant Receivables, Net

The tenant receivable balance as of March 31, 2024 June 30, 2024 and December 31, 2023 was \$7,743 \$8,073 and \$6,762, respectively. The balance as of March 31, 2024 June 30, 2024 consisted of \$3,444 \$3,938 in funds owed from the Company's tenants for rent that the Company had earned but had not yet received, \$3,886 \$3,531 of tenant reimbursements, \$128 \$125 for a loan that was made to one of the Company's tenants, and \$285 \$479 of miscellaneous receivables. The balance as of December 31, 2023 consisted of \$2,062 in funds owed from the Company's tenants for rent that the Company had earned but had not yet received, \$4,372 of tenant reimbursements, \$131 for a loan that was made to one of the Company's tenants, and \$197 of miscellaneous receivables.

Receivables arising from operating leases are accounted for in accordance with ASC Topic 842 "Leases" ("ASC Topic 842"). The Company assesses the likelihood of losses resulting from tenant defaults, or the inability of tenants to make contractual rent and tenant reimbursements at each reporting date. The Company also monitors the liquidity and creditworthiness of its tenants and operators on a continuous basis. If the likelihood of a tenant paying its lease payments is determined to no longer be probable, all tenant receivables, including deferred rent, are written off against revenue and any future revenue for that tenant is recognized only upon receipt of cash.

[Table of Contents](#)

In addition, as of **March 31, 2024** **June 30, 2024** and December 31, 2023, the Company had a portfolio level reserve of \$350 on those leases that were probable of collection to ensure that the tenant lease receivables were not overstated.

Escrow Deposits

The escrow balance as of **March 31, 2024** **June 30, 2024** and December 31, 2023 was **\$737** **\$925** and \$673, respectively. Escrow deposits include funds held in escrow to be used for the acquisition of properties in the future and for the payment of taxes and insurance.

Deferred Assets

The deferred assets balance as of **March 31, 2024** **June 30, 2024** and December 31, 2023 was **\$27,995** **\$28,360** and \$27,132, respectively. The balance as of **March 31, 2024** **June 30, 2024** consisted of **\$27,157** **\$27,484** in deferred rent receivables resulting from the recognition of revenue from leases with fixed annual rental escalations on a straight-line basis and **\$838** **\$876** of other deferred costs. The balance as of December 31, 2023 consisted of \$26,757 in deferred rent receivables resulting from the recognition of revenue from leases with fixed annual rental escalations on a straight-line basis and \$375 of other deferred costs.

Other Assets

The other assets balance as of **March 31, 2024** **June 30, 2024** and December 31, 2023 was **\$17,874** **\$18,530** and \$15,722, respectively. The balance as of **March 31, 2024** **June 30, 2024** consisted of **\$7,613** **\$7,451** in right of use assets, **\$3,854** **\$4,904** in capitalized construction in process costs, **\$2,538** **\$1,880** in prepaid assets, **\$3,445** **\$3,891** in net capitalized leasing commissions, and **\$424** **\$404** in net capitalized software costs and miscellaneous assets. The balance as of December 31, 2023 consisted of \$7,627 in right of use assets, \$3,346 in capitalized construction in process costs, \$1,379 in prepaid assets, \$2,894 in net capitalized leasing commissions, and \$476 in net capitalized software costs and miscellaneous assets. Refer to Note 8 – “Leases” for additional details on right of use assets.

Derivative Instruments - Interest Rate Swaps

As of **March 31, 2024** **June 30, 2024** and December 31, 2023, the Company's balance related to interest rate swap derivative instruments that were designated as cash flow hedges of interest rate risk was an asset of **\$29,285** **\$27,672** and \$25,125, respectively. In accordance with the Company's risk management strategy, the purpose of the interest rate swaps is to manage interest rate risk for certain of the Company's variable-rate debt. The interest rate swaps involve the Company's receipt of variable-rate amounts from the counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company accounts for derivative instruments in accordance with the provisions of ASC Topic 815, “Derivatives and Hedging.” Refer to Note 4 – “Credit Facility, Notes Payable and Derivative Instruments” for additional details.

Goodwill

As of **March 31, 2024** **June 30, 2024** and December 31, 2023, the Company's goodwill balance was \$5,903. Goodwill represents the excess of consideration paid over the fair value of underlying identifiable net assets of businesses acquired. Goodwill has an indefinite life and is not amortized, but is tested for impairment on an annual basis, or more frequently if events or changes in circumstances indicate that the asset might be impaired. The Company's policy is to perform its annual goodwill impairment evaluation as of the first day of the fourth quarter of its fiscal year. The Company has one reporting unit.

Assets Held for Sale and Sales of Real Estate

The Company classifies a property as held for sale when the following criteria are met: (i) management, having the authority to approve action, commits to a plan to sell the property in its present condition, (ii) the sale of the property is at a price reasonable in relation to its current fair value and (iii) the sale is probable and expected to be completed within one year. At that time, the Company presents the assets and obligations associated with the real estate held for sale separately in its Condensed Consolidated Balance Sheets and ceases recording depreciation and amortization expense related to that asset. Real estate held for sale is reported at the lower of its carrying amount or its estimated fair value less estimated costs to sell. None of the Company's properties were classified as held for sale as of **March 31, 2024** **June 30, 2024** or December 31, 2023.

Upon the disposition of a property, the Company recognizes a gain or loss at a point in time when the Company determines control of the underlying asset has been transferred to the buyer. The Company's performance obligation is generally satisfied at the

-10-

closing of the transaction. Any continuing involvement is analyzed as a separate performance obligation in the contract, and a portion of the sales price is allocated to each performance obligation. There is significant judgment applied to estimate the amount of variable consideration, if any, identified within the sales price and assess its probability of occurrence based on current market information, historical transactions, and forecasted information that is reasonably available.

For sales of real estate (or assets classified as held for sale), the Company evaluates whether the disposition is a strategic shift that will have a major effect on the Company's operations and financial results, and, if so, it will be classified as discontinued operations in the Company's consolidated financial statements for all periods presented.

Other Liabilities

The other liabilities balance as of **March 31, 2024** **June 30, 2024** and December 31, 2023 was **\$12,952** **\$12,809** and \$12,770, respectively. The balance as of **March 31, 2024** **June 30, 2024** consisted of **\$7,835** **\$7,707** for right of use liabilities and **\$5,117** **\$5,102** of prepaid rent. The balance as of December 31, 2023 consisted of \$7,680 for right of use liabilities and \$5,090 of prepaid rent. Refer to Note 8 – "Leases" for additional details on right of use liabilities.

Note 3 – Property Portfolio

Summary of Properties Acquired and Sold During the **Three Six Months Ended** **March 31, 2024** **June 30, 2024**

During the **three six** months ended **March 31, 2024** **June 30, 2024**, the Company completed no acquisitions **or dispositions.** and completed one disposition. In June 2024, the Company sold an in-patient rehabilitation facility located in Mishawaka, Indiana receiving gross proceeds of \$8.1 million, resulting in a loss of \$3.4 million.

A rollforward of the gross investment in land, building, improvements, and acquired lease intangible assets as of **March 31, 2024** **June 30, 2024** is as follows:

	March 31, 2024						June 30, 2024					
	Land	Building	Site Improvements	Tenant Improvements	Acquired Lease Intangible Assets	Gross Investment in Real Estate	Land	Building	Site Improvements	Tenant Improvements	Acquired Lease Intangible Assets	Gross Investment in Real Estate
Balances as of December 31, 2023	\$164,315	\$1,035,705	\$ 21,974	\$ 66,358	\$ 138,617	\$ 1,426,969	\$164,315	\$1,035,705	\$ 21,974	\$ 66,358	\$ 138,617	\$ 1,426,969
Capitalized costs(1)	—	519	10	663	—	1,192	—	2,918	61	1,444	—	4,433
Total	—	519	10	663	—	1,192	—	2,918	61	1,444	—	4,433
Balances as of March 31, 2024	\$164,315	\$1,036,224	\$ 21,984	\$ 67,021	\$ 138,617	\$ 1,428,161	\$164,315	\$1,038,623	\$ 22,035	\$ 67,792	\$ 138,617	\$ 1,432,592

Disposition of Mishawaka					
- 6/27/24	(1,924)	(10,084)	(75)	(1,798)	(2,223)
Balances as of June 30, 2024	\$162,391	\$1,028,539	\$ 21,960	\$ 66,004	\$ 136,394

(1) Represents capital projects that were completed and placed in service during the **three** **six** months ended **March 31, 2024** **June 30, 2024** related to the Company's existing facilities.

Depreciation expense was **\$10,113** **\$10,127** and **\$10,494** **\$20,240** for the three and six months ended **March 31, 2024** **June 30, 2024**, respectively, and **2023**, **\$10,468** and **\$20,962** for the three and six months ended **June 30, 2023**, respectively.

As of **March 31, 2024** **June 30, 2024**, the Company had aggregate capital improvement commitments and obligations to improve, expand, and maintain the Company's existing facilities of approximately **\$19,600**, **\$16,800**. Many of these amounts are subject to contingencies that make it difficult to predict when they will be utilized, if at all. In accordance with the terms of the Company's leases, capital improvement obligations in the next twelve months are expected to total approximately **\$13,900**, **\$13,600**.

Summary of Properties Acquired and Sold During the Year Ended December 31, 2023

During the year ended December 31, 2023 the Company completed one acquisition. For this acquisition, substantially all of the fair value was concentrated in a single identifiable asset or group of similar identifiable assets and, therefore, this acquisition represents an asset acquisition. Accordingly, transaction costs for this acquisition were capitalized.

-12-

[Table of Contents](#)

During the year ended December 31, 2023, the Company completed three dispositions. In March 2023, the Company sold a medical office building located in Jacksonville, Florida receiving gross proceeds of \$4.4 million, resulting in a gain of \$0.5 million. In June 2023, the Company sold a portfolio of four medical office buildings located in Oklahoma City, Oklahoma receiving gross proceeds of \$66.0 million, resulting in a gain of \$12.8 million. In August 2023, the Company sold a medical office building located in North Charleston, South Carolina receiving gross proceeds of \$10.1 million, resulting in a gain of \$2.3 million.

-11-

[Table of Contents](#)

A rollforward of the gross investment in land, building, improvements, and acquired lease intangible assets as of December 31, 2023 is as follows:

	Land	Building	Site Improvements	Tenant Improvements	Acquired Lease Intangible Assets	Gross Investment in Real Estate
Balances as of December 31, 2022	\$ 168,308	\$ 1,079,781	\$ 22,024	\$ 65,987	\$ 148,077	\$ 1,484,177
Facility Acquired – Date Acquired:						
Redding – 4/17/23	771	3,798	174	321	872	5,936
Capitalized costs ⁽¹⁾	—	3,146	1,009	2,356	172	6,683
Total Additions:	771	6,944	1,183	2,677	1,044	12,619
Disposition of Jacksonville – 3/9/2023	(1,023)	(2,827)	—	—	—	(3,850)
Disposition of Oklahoma City – 6/30/2023	(2,814)	(43,553)	(1,127)	(1,505)	(9,406)	(58,405)
Disposition of North Charleston – 8/1/2023	(927)	(4,640)	(106)	(801)	(1,098)	(7,572)
Total Dispositions:	(4,764)	(51,020)	(1,233)	(2,306)	(10,504)	(69,827)

Balances as of December 31, 2023	\$ 164,315	\$ 1,035,705	\$ 21,974	\$ 66,358	\$ 138,617	\$ 1,426,969
----------------------------------	------------	--------------	-----------	-----------	------------	--------------

⁽¹⁾ Represents capital projects that were completed and placed in service during the year ended December 31, 2023 related to the Company's existing facilities.

Lease Intangible Assets and Liabilities

The following is a summary of the carrying amount of lease intangible assets and liabilities as of the dates presented:

	As of March 31, 2024			As of June 30, 2024		
	Accumulated			Accumulated		
	Cost	Amortization	Net	Cost	Amortization	Net
Assets						
In-place leases	\$ 77,037	\$ (46,924)	\$ 30,113	\$ 75,572	\$ (48,197)	\$ 27,375
Above market leases	24,961	(11,137)	13,824	24,725	(11,736)	12,989
Leasing costs	36,619	(19,744)	16,875	36,097	(20,436)	15,661
	<u>\$ 138,617</u>	<u>\$ (77,805)</u>	<u>\$ 60,812</u>	<u>\$ 136,394</u>	<u>\$ (80,369)</u>	<u>\$ 56,025</u>
Liability						
Below market leases	\$ 13,595	\$ (8,882)	\$ 4,713	\$ 13,595	\$ (9,446)	\$ 4,149

	As of December 31, 2023		
	Accumulated		
	Cost	Amortization	Net
Assets			
In-place leases	\$ 77,037	\$ (44,249)	\$ 32,788
Above market leases	24,961	(10,318)	14,643
Leasing costs	36,619	(18,556)	18,063
	<u>\$ 138,617</u>	<u>\$ (73,123)</u>	<u>\$ 65,494</u>
Liability			
Below market leases	\$ 13,595	\$ (8,314)	\$ 5,281

The following is a summary of the acquired lease intangible amortization:

	Three Months Ended	
	March 31,	
	2024	2023
Amortization expense related to in-place leases	\$ 2,675	\$ 3,048
Amortization expense related to leasing costs	\$ 1,188	\$ 1,325
Decrease in rental revenue related to above market leases	\$ 819	\$ 876
Increase in rental revenue related to below market leases	\$ (568)	\$ (585)

-12- -13-

[Table of Contents](#)

The following is a summary of the acquired lease intangible amortization:

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2024	2023	2024	2023
Amortization expense related to in-place leases	\$ 2,601	\$ 2,993	\$ 5,276	\$ 6,041

Amortization expense related to leasing costs	\$ 1,165	\$ 1,313	\$ 2,353	\$ 2,638
Decrease in rental revenue related to above market leases	\$ 813	\$ 871	\$ 1,632	\$ 1,747
Increase in rental revenue related to below market leases	\$ (564)	\$ (584)	\$ (1,132)	\$ (1,169)

As of **March 31, 2024** **June 30, 2024**, scheduled future aggregate net amortization of the acquired lease intangible assets and liabilities for each year ended December 31 is listed below:

	Net Decrease in Revenue	Net Increase in Expenses	Net Decrease in Revenue	Net Increase in Expenses
2024 (nine months remaining)	\$ (903)	\$ 10,347		
2024 (six months remaining)			\$ (635)	\$ 6,411
2025	(1,696)	10,526	(1,694)	10,514
2026	(1,802)	8,700	(1,801)	8,699
2027	(1,375)	6,114	(1,375)	6,113
2028	(1,091)	4,805	(1,091)	4,805
Thereafter	(2,244)	6,496	(2,244)	6,494
Total	\$ (9,111)	\$ 46,988	\$ (8,840)	\$ 43,036

As of **March 31, 2024** **June 30, 2024**, the weighted average amortization periods for asset lease intangibles and liability lease intangibles were **3.3** **3.2** years and **2.1** **1.8** years, respectively.

Note 4 – Credit Facility, Notes Payable and Derivative Instruments

Credit Facility

The Company, the Operating Partnership, as borrower, and certain of its subsidiaries (such subsidiaries, the “Subsidiary Guarantors”) are parties to an amended and restated \$900 million unsecured syndicated credit facility with JPMorgan Chase Bank, N.A. (“JPMorgan”), as administrative agent (the “Credit Facility”). The Credit Facility consists of (i) \$500 million of term loans, which include (a) a \$350 million term loan (“Term Loan A”) and (b) a \$150 million term loan (“Term Loan B,” and, together with Term Loan A, the “Term Loans”), and (ii) a \$400 million revolver (the “Revolver”). The Credit Facility also includes a \$500 million accordion feature. Term Loan A matures in May 2026, Term Loan B matures in February 2028, and the Revolver matures in August 2026, with two six-month extension options. Interest rates on amounts outstanding under the Credit Facility equal the term Secured Overnight Financing Rate (“SOFR”**SOFR**) plus a related spread adjustment of 10 basis points and a borrowing spread based on the current pricing grid in the Credit Facility. The Company may be entitled to a temporary reduction in the interest rate of two basis points provided it meets certain to be agreed upon sustainability goals.

The Operating Partnership is subject to a number of financial covenants under the Credit Facility, including, among other things, the following as of the end of each fiscal quarter, (i) a maximum consolidated unsecured leverage ratio of less than 60%, (ii) a maximum consolidated secured leverage ratio of less than 30%, (iii) a maximum consolidated secured recourse leverage ratio of less than 10%, (iv) a minimum fixed charge coverage ratio of 1.50:1.00, (v) a minimum unsecured interest coverage ratio of 1.50:1.00, (vi) a maximum consolidated leverage ratio of less than 60%, and (vii) a minimum net worth of \$573 million plus 75% of all net proceeds raised through equity offerings subsequent to March 31, 2022. As of **March 31, 2024** **June 30, 2024**, management believed it complied with all of the financial and non-financial covenants contained in the Credit Facility.

The Company has entered into interest rate swaps to hedge its interest rate risk on the Term Loans through their respective maturities. For additional information related to the interest rate swaps, see the “Derivative Instruments - Interest Rate Swaps” section herein.

During the three months ended March 31, 2024, the Company borrowed \$14,000 under the Credit Facility and repaid \$7,800, for a net amount borrowed of \$6,200. During the three months ended March 31, 2023, the Company borrowed \$12,600 under the Credit Facility and repaid \$14,800, for a net amount repaid of \$2,200. Interest expense incurred on the Credit Facility was \$6,055 and \$6,988 for the three months ended March 31, 2024 and 2023, respectively.

-13- -14-

[Table of Contents](#)

During the six months ended June 30, 2024, the Company borrowed \$38,500 under the Credit Facility and repaid \$25,900, for a net amount borrowed of \$12,600. During the six months ended June 30, 2023, the Company borrowed \$24,600 under the Credit Facility and repaid \$94,157, for a net amount repaid of \$69,557. Interest expense incurred on the Credit Facility was \$6,184 and \$12,240 for the three and six months ended June 30, 2024, respectively, and \$7,181 and \$14,169 for the three and six months ended June 30, 2023, respectively.

As of March 31, 2024, June 30, 2024 and December 31, 2023, the Company had the following outstanding borrowings under the Credit Facility:

	March 31, 2024	December 31, 2023	June 30, 2024	December 31, 2023
Revolver	\$ 98,600	\$ 92,400	\$ 105,000	\$ 92,400
Term Loan A	350,000	350,000	350,000	350,000
Term Loan B	150,000	150,000	150,000	150,000
Credit Facility, gross	598,600	592,400	605,000	592,400
Less: Unamortized debt issuance costs	(6,518)	(7,067)	(5,968)	(7,067)
Credit Facility, net	\$ 592,082	\$ 585,333	\$ 599,032	\$ 585,333

Costs incurred related to the Credit Facility, net of accumulated amortization, are netted against the Company's Credit Facility, net of unamortized debt issuance costs" balance in the accompanying Condensed Consolidated Balance Sheets. Amortization expense incurred related to debt issuance costs was \$549 \$550 and \$1,099 for each of the three and six months ended March 31, 2024 June 30, 2024, respectively, and 2023 \$549 and \$1,098 for the three and six months ended June 30, 2023, respectively, and is included in the "Interest Expense" line item in the accompanying Condensed Consolidated Statements of Operations.

Notes Payable, Net of Debt Issuance Costs

The Company, through certain of its wholly owned subsidiaries, entered into or assumed loans in connection with the acquisitions of the Rosedale, Dumfries, and Toledo facilities. The Dumfries loan matured and was paid in full in June 2024. As of March 31, 2024, June 30, 2024 and December 31, 2023, the Company had the following outstanding borrowings under these loans:

	March 31, 2024	December 31, 2023	June 30, 2024	December 31, 2023
Rosedale loan (1)	\$ 13,462	\$ 13,563	\$ 13,362	\$ 13,563
Dumfries loan (2)	10,957	11,034	—	11,034
Toledo loan (3)	1,316	1,368	1,316	1,368
Notes payable, gross	25,735	25,965	14,678	25,965
Unamortized debt issuance costs	(53)	(66)	(40)	(66)
Notes payable, net	\$ 25,682	\$ 25,899	\$ 14,638	\$ 25,899

(1) The Rosedale loan has an annual interest rate of 3.85% and matures on July 31, 2025.

(2) The Dumfries loan has had an annual interest rate of 4.68% and matures matured on June 1, 2024.

(3) The Toledo loan has an annual interest rate of 5.0% and matures on July 30, 2033.

Amortization expense incurred related to the debt issuance costs was \$13 and \$39 \$26 for the three and six months ended March 31, 2024 June 30, 2024, respectively, and 2023, \$38 and \$77 for the three and six months ended June 30, 2023, respectively, and is included in the "Interest Expense" line item in the accompanying Condensed Consolidated Statements of Operations.

The Company made principal payments of \$230 \$11,287 and \$344 \$628 during the three six months ended March 31, 2024 June 30, 2024 and 2023, respectively. Interest expense incurred on these loans was \$273 \$245 and \$695 \$518 for the three and six months ended March 31, 2024 June 30, 2024, respectively, and 2023, \$700 and \$1,395 for the three and six months ended June 30, 2023, respectively.

As of March 31, 2024, scheduled principal payments due for each year ended December 31 were as follows:

2024 (nine months remaining)	\$ 11,314
2025	13,268
2026	117
2027	124
2028	131
Thereafter	781
Total	\$ 25,735

[Table of Contents](#)

As of June 30, 2024, scheduled principal payments due for each year ended December 31 were as follows:

2024 (six months remaining)	\$ 257
2025	13,268
2026	117
2027	124
2028	131
Thereafter	781
Total	<u>\$ 14,678</u>

Derivative Instruments - Interest Rate Swaps

The Company has ten interest rate swaps and three forward starting interest rate swaps that are used to manage its interest rate risk by fixing the SOFR component of the Term Loans through their maturities. A description of these swaps is below:

Term Loan A Swaps

As of **March 31, 2024** **June 30, 2024**, six of the Company's interest rate swaps related to Term Loan A. The combined notional value of these swaps is \$350 million, with \$200 million of the swaps maturing in August 2024 and the remaining \$150 million maturing in April 2026. In addition, the Company has three forward starting interest rate swaps with a combined notional value of \$200 million, each with a maturity date of April 2026, that will become effective on the August 2024 maturity date of the existing swaps noted above. Currently, the Term Loan A swaps fix the SOFR component of Term Loan A at a rate of 1.50% through August 2024. From August 2024 to April 2026 the SOFR component of Term Loan A will be fixed at 1.36%.

Term Loan B Swaps

As of **March 31, 2024** **June 30, 2024**, four of the Company's interest rate swaps related to Term Loan B with a combined notional value of \$150 million that fix the SOFR component of Term Loan B through January 2028 at 2.54%.

The Company records the swaps either as an asset or a liability measured at its fair value at each reporting period. When hedge accounting is applied, the change in the fair value of derivatives designated and that qualify as cash flow hedges is (i) recorded in accumulated other comprehensive income in the equity section of the Company's Condensed Consolidated Balance Sheets and (ii) subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transactions affect earnings. If specific hedge accounting criteria are not met, changes in the Company's derivative instruments' fair value are recognized currently as an adjustment to net income. As of **March 31, 2024** **June 30, 2024** and December 31, 2023, all of the Company's swaps meet the criteria for hedge accounting.

The Company's interest rate swaps are not traded on an exchange. The Company's interest rate swaps are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis based on the expected size of future cash flows on a discounted basis and incorporates a measure of non-performance risk. The fair values are based on Level 2 inputs within the framework of ASC Topic 820. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivative instruments.

The fair value of the Company's interest rate swaps was an asset of **\$29,285** **\$27,672** and \$25,125 as of **March 31, 2024** **June 30, 2024** and December 31, 2023, respectively. The balances are included in the "Derivative Asset" line item on the Company's Condensed Consolidated Balance Sheets as of **March 31, 2024** **June 30, 2024** and December 31, 2023, respectively.

The table below details the components of the amounts presented on the accompanying Condensed Consolidated Statements of Comprehensive **(Loss)** Income recognized on the Company's interest rate swaps designated as cash flow hedges for the three **and six** months ended **March 31, 2024** **June 30,**

2024 and 2023:

	Three Months Ended March 31,	
	2024	2023
Amount of (gain) loss recognized in other comprehensive income (loss)	\$ (8,610)	\$ 4,157
Amount of gain reclassified from accumulated other comprehensive income into interest expense	4,450	3,107
Total change in accumulated other comprehensive income	\$ (4,160)	\$ 7,264

-16-

[Table of Contents](#)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Amount of gain recognized in other comprehensive (loss) income	\$ (2,820)	\$ (12,180)	\$ (11,430)	\$ (8,023)
Amount of gain reclassified from accumulated other comprehensive income into interest expense	4,433	3,731	8,883	6,838
Total change in accumulated other comprehensive income	\$ 1,613	\$ (8,449)	\$ (2,547)	\$ (1,185)

During the next twelve months, the Company estimates that an additional \$15,576 \$15,684 will be reclassified as a decrease to interest expense. Additionally, during the three and six months ended March 31, 2024 June 30, 2024, the Company recorded total interest expense in its Condensed Consolidated Statements of Operations of \$6,890, \$6,992 and \$13,883, respectively.

Weighted-Average Interest Rate and Term

The weighted average interest rate and term of the Company's debt was 3.85% 3.89% and 2.7 2.5 years at March 31, 2024 June 30, 2024, compared to 3.83% and 2.9 years as of December 31, 2023.

-15-

[Table of Contents](#)

Note 5 – Equity

Preferred Stock

The Company's charter authorizes the issuance of 10,000 shares of preferred stock, par value \$0.001 per share. As of March 31, 2024 June 30, 2024 and December 31, 2023, there were 3,105 shares of Series A Cumulative Redeemable Preferred Stock ("Series A Preferred Stock"), issued and outstanding. The Series A Preferred Stock has a liquidation preference of \$25 per share.

Preferred stock dividend activity for the three six months ended March 31, 2024 June 30, 2024 is summarized in the following table:

Date Announced	Applicable			Quarterly Dividends		Applicable			Quarterly Dividends	
	Record Date	Quarter	Payment Date	Dividend	per Share	Record Date	Quarter	Payment Date	Dividend	per Share
December 12, 2023	January 15, 2024	Q4 2023	January 31, 2024	\$ 1,455	\$ 0.46875	January 15, 2024	Q4 2023	January 31, 2024	\$ 1,455	\$ 0.46875
March 7, 2024	April 15, 2024	Q1 2024	April 30, 2024	\$ 1,455	\$ 0.46875 ⁽¹⁾	April 15, 2024	Q1 2024	April 30, 2024	\$ 1,455	\$ 0.46875

June 6, 2024	July 15, 2024	Q2 2024	July 31, 2024	\$ 1,455	⁽¹⁾ \$0.46875
--------------	---------------	---------	---------------	----------	--------------------------

(1) Two months of this amount, equal to \$970, was accrued at **March 31, 2024** **June 30, 2024**.

The holders of the Series A Preferred Stock are entitled to receive dividend payments only when, as and if declared by the Company's board of directors (the "Board") (or a duly authorized committee of the Board). Dividends will accrue or be payable in cash from the original issue date, on a cumulative basis, quarterly in arrears on each dividend payment date at a fixed rate per annum equal to 7.50% of the liquidation preference of \$25.00 per share (equivalent to \$1.875 per share on an annual basis). The Series A Preferred Stock may be partially or fully redeemed by the Company. Dividends on the Series A Preferred Stock are cumulative and accrue whether or not (i) funds are legally available for the payment of those dividends, (ii) the Company has earnings or (iii) those dividends are declared by the Board. The quarterly dividend payment dates on the Series A Preferred Stock are January 31, April 30, July 31 and October 31 of each year. During each of the **three-month** **six-month** periods ended **March 31, 2024** **June 30, 2024** and 2023, the Company paid preferred dividends of **\$1,455**, **\$2,911**.

Common Stock

The Company has 500,000 authorized shares of common stock, \$0.001 par value. As of **March 31, 2024** **June 30, 2024** and December 31, 2023, there were **65,587** **65,588** and 65,565 outstanding shares of common stock, respectively.

-17-

[Table of Contents](#)

Common stock dividend activity for the **three six** months ended **March 31, 2024** **June 30, 2024** is summarized in the following table:

Date Announced	Applicable			Dividend		Dividends per Share	Applicable			Dividend		Dividends per Share
	Record Date	Quarter	Payment Date	Amount ⁽¹⁾			Record Date	Quarter	Payment Date	Amount ⁽¹⁾		
December 12, 2023	December 27, 2023	Q4 2023	January 9, 2024	\$ 14,819	\$	0.21	December 27, 2023	Q4 2023	January 9, 2024	\$14,819	\$	0.21
March 7, 2024	March 22, 2024	Q1 2024	April 9, 2024	\$ 14,901	\$	0.21	March 22, 2024	Q1 2024	April 9, 2024	\$14,901	\$	0.21
June 6, 2024							June 21, 2024	Q2 2024	July 9, 2024	\$14,912	\$	0.21

(1) Includes distributions on outstanding LTIP Units and OP Units.

During the **three six** months ended **March 31, 2024** **June 30, 2024** and 2023, the Company paid total dividends on its common stock, LTIP Units and OP Units in the aggregate amount of **\$14,946** **\$29,846** and **\$14,699**, **\$29,387**, respectively.

As of **March 31, 2024** **June 30, 2024** and December 31, 2023, the Company had accrued dividend balances of **\$285** **\$398** and \$345 for dividends payable on the aggregate annual and long-term LTIP Units that are subject to retroactive receipt of dividends on the amount of LTIP Units ultimately earned. During the **three six** months ended **March 31, 2024** **June 30, 2024**, **\$67** **\$180** of dividends were accrued and \$127 of dividends were paid related to these units. During the **three six** months ended **March 31, 2023** **June 30, 2023**, **\$44** **\$107** of dividends were accrued and \$57 of dividends were paid related to these units.

The amount of the dividends paid to the Company's stockholders is determined by the Board and is dependent on a number of factors, including funds available for payment of dividends, the Company's financial condition and capital expenditure requirements, except that, in accordance with the Company's organizational documents and Maryland law, the Company may not make dividend distributions that would: (i) cause it to be unable to pay its debts as they become due in the usual course of business; (ii) cause its total

-16-

assets to be less than the sum of its total liabilities plus senior liquidation preferences; or (iii) jeopardize its ability to maintain its qualification as a REIT.

In January 2024, the Company and the Operating Partnership implemented a \$300 million “at-the-market” equity offering program, pursuant to which the Company may offer and sell (including through forward sales), from time to time, shares of its common stock (the “2024 ATM Program”). No shares were sold under the 2024 ATM Program during the **three six** months ended **March 31, 2024 June 30, 2024**.

OP Units

During the **three six** months ended **March 31, 2024 June 30, 2024**, the Operating Partnership did not issue or redeem any OP Units. During the year ended December 31, 2023, the Operating Partnership issued 577 OP Units with a value of \$5,482 in connection with a facility acquisition and did not redeem any OP Units.

As of March 31, 2024 and December 31, 2023, there were 2,244 OP Units issued and outstanding, with an aggregate value of \$13,962. The OP Unit value at issuance and redemption is based on the Company’s closing share price on the date of the respective transaction and is included as a component of noncontrolling interest equity in the Company’s Condensed Consolidated Balance Sheets as of **March 31, 2024 June 30, 2024** and December 31, 2023. **As of June 30, 2024 and December 31, 2023, there were 2,244 OP Units issued and outstanding.** The Company has sufficient shares of common stock authorized pursuant to its charter to cover the redemption of outstanding OP Units.

Note 6 – Related Party Transactions

Related Party Balances

The amounts due from related parties as of **March 31, 2024 June 30, 2024** and December 31, 2023 were **\$363 \$410** and \$193, respectively. These balances primarily consist of taxes paid on behalf of LTIP Unit and OP Unit holders that are reimbursable to the Company. The Company had no amounts due to related parties as of **March 31, 2024 June 30, 2024** and December 31, 2023.

-18-

Note 7 – Stock-Based Compensation

2016 Equity Incentive Plan

The 2016 Equity Incentive Plan, as amended (the “Plan”), is intended to assist the Company and its affiliates in recruiting and retaining employees of the Company, members of the Board, executive officers of the Company, and individuals who provide services to the Company and its affiliates.

The Plan is intended to permit the grant of both qualified and non-qualified options and the grant of stock appreciation rights, restricted stock, unrestricted stock, awards of restricted stock units, performance awards and other equity-based awards (including LTIP Units). Based on the grants outstanding as of **March 31, 2024 June 30, 2024**, there were **455 1,901** shares of common stock that remain available to be granted under the Plan. Units subject to awards under the Plan that are forfeited, cancelled, lapsed, or otherwise expired (excluding shares withheld to satisfy exercise prices or tax withholding obligations) are available for grant.

-17-

Time-Based Grants

During the **three** **six** months ended **March 31, 2024** **June 30, 2024**, the Company granted the following LTIP **Units were issued by the Company: Units:**

Date	Description	Number of Units Issued	Vesting Dates
February 21, 2024	Final awards under the 2023 Annual Incentive Plan	151	50% on February 21, 2024; and 50% on February 21, 2025
February 21, 2024	Time-based awards under the 2024 Long-Term Incentive Plan	238	100% on February 21, 2027
May 15, 2024	Annual awards to independent directors	47	100% vest on May 15, 2025
June 10, 2024	Discretionary grant	8	33.33% on June 10, 2025; 33.33% on June 10, 2026; and 33.33% on June 10, 2027;

During the **three** **six** months ended **March 31, 2024** **June 30, 2024**, certain participants redeemed an aggregate of **22** **23** vested LTIP Units for the Company's common stock. A detail of the Company's outstanding time-based LTIP Units as of **March 31, 2024** **June 30, 2024** is as follows:

Vested units	2,403 2,450
Unvested units	720 727
LTIP Units outstanding as of March 31, 2024 June 30, 2024	3,123 3,177

Performance Based Awards

The Board has approved annual performance-based LTIP awards ("Annual Awards") and long-term performance-based LTIP awards ("Long-Term Awards" and together with the Annual Awards, "Performance Awards") to the executive officers and other employees of the Company. As described below, the Annual Awards have one-year performance periods and the Long-Term Awards have three-year performance periods. In addition to meeting specified performance metrics, vesting in the Performance Awards is subject to service requirements.

-19-

[Table of Contents](#)

A detail of the Performance Awards under the 2022, 2023 and 2024 programs as of **March 31, 2024** **June 30, 2024** is as follows:

2022 Long-Term Awards	96
2023 Long-Term Awards	154
2024 Annual Awards (1)	147 152
2024 Long-Term Awards (2)	228
Total target Performance Awards as of March 31, 2024 June 30, 2024	625 630

(1) Approved by the Board on February 21, 2024. The number of target LTIP Units was based on the average closing price of the Company's common stock reported on the New York Stock Exchange over the 15 trading days preceding the award date.

(2) Approved by the Board on February 21, 2024. The number of target LTIP Units was based on the fair value of the Long-Term Awards as determined by an independent valuation **consultant** **consultant**.

Annual Awards. The Annual Awards are subject to the terms and conditions of LTIP Annual Award Agreements ("LTIP Annual Award Agreements") between the Company and each grantee.

The Compensation Committee of the Board (the "Compensation Committee") and the Board established performance goals for the year ending December 31, 2024, as set forth in the 2024 LTIP Annual Award Agreements (the "Performance Goals") that will be used to determine the number of LTIP

Units earned by each grantee. Cumulative stock-based compensation expense during the three **and six** months ended **March 31, 2024** **June 30, 2024** reflects management's estimate of the probability of the number of these awards that will be earned. As soon as reasonably practicable following the end of the performance period, the Compensation Committee and the Board will determine the extent to which the Company has achieved each of the Performance Goals (expressed as a percentage) and, based on such determination, will calculate the number of LTIP Units that each grantee is entitled to receive. Each grantee may earn up to 150% of the number of his/her target LTIP Units. Any 2024 Annual Award LTIP Units that are not earned will be forfeited and cancelled.

Vesting. LTIP Units that are earned as of the end of the applicable performance period will vest in two installments as follows: 50% of the earned LTIP Units will become vested on the valuation date of the awards (which is expected to occur in February 2025)

-18-

[Table of Contents](#)

and 50% of the earned LTIP Units become vested on the one year anniversary of the initial vesting date. Vesting may be accelerated under certain circumstances such as a "change-in-control" transaction or a "qualified termination" event.

Distributions. Distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the estimated maximum number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.

Long-Term Awards. The Long-Term Awards are subject to the terms and conditions of their related LTIP Long-Term Award Agreements (collectively the "LTIP Long-Term Award Agreements") between the Company and each grantee. The number of LTIP Units that each grantee earns under the LTIP Long-Term Award Agreements will be determined following the conclusion of a three-year performance period based on the Company's (i) total stockholder return ("TSR"), which is determined based on a combination of appreciation in stock price and dividends paid during the performance period, and (ii) relative stockholder return ("RSR"), which is determined by comparing the Company's TSR with the TSRs of the companies that comprise the Dow Jones U.S. Real Estate Health Care Index (the "Index"). Each grantee may earn up to 200% of the number of target LTIP Units covered by the grantee's Long-Term Award. Any target LTIP Units that are not earned will be forfeited and cancelled. The number of LTIP Units earned under the Long-Term Awards will be determined as soon as reasonably practicable following the end of the applicable three-year performance period based on the Company's TSR on an absolute basis (as to 50% of the Long-Term Award) and RSR (as to 50% of the Long-Term Award).

Vesting. LTIP Units that are earned as of the end of the applicable three-year performance period will vest in two installments as follows: 50% of the earned LTIP Units will vest upon the day prior to the third anniversary of the respective grant dates and the remaining 50% will vest on the one year anniversary of the initial vesting date. Vesting may be accelerated under certain circumstances such as a "change-in-control" transaction or a "qualified termination" event.

Distributions. Pursuant to the LTIP Long-Term Award Agreements, distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the estimated maximum number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.

-20-

[Table of Contents](#)

Stock-Based Compensation Expense

Compensation expense for LTIP Unit grants, Annual Awards, and Long-Term Awards is based on the grant date fair value of the units/awards, with no subsequent remeasurement required.

As the Long-Term Awards involve market-based performance conditions, the Company utilizes a Monte Carlo simulation to provide a grant date fair value for expense recognition. The Monte Carlo simulation is a generally accepted statistical technique used, in this instance, to simulate a range of possible

future stock prices for the Company and the members of the Index over the Performance Periods. The purpose of this modeling is to use a probabilistic approach for estimating the fair value of the performance share award.

The assumptions used in the Monte Carlo simulation include beginning average stock price, valuation date stock price, expected volatilities, correlation coefficients, risk-free rate of interest, and expected dividend yield. The beginning average stock price is the beginning average stock price for the Company and each member of the Index for the 15 trading days leading up to the grant date of the Long-Term Award. The valuation date stock price is the closing stock price of the Company and each of the peer companies in the Index on the grant dates of the Long-Term Awards. The expected volatilities are modeled using the historical volatilities for the Company and the members of the Index. The correlation coefficients are calculated using the same data as the historical volatilities. The risk-free rate of interest is taken from the U.S. Treasury website and relates to the expected life of the remaining performance period on valuation or revaluation. Lastly, the dividend yield assumption is 0.0%, which is mathematically equivalent to reinvesting dividends in the issuing entity, which is part of the Company's award agreement assumptions.

-19-

Table of Contents

Below are details regarding certain of the assumptions for the Long-Term Awards using Monte Carlo simulations:

	2024 Long-Term Awards	2023 Long-Term Awards	2022 Long-Term Awards
Fair value	\$ 9.37	\$ 11.67	\$ 16.39
Target awards	228	154	96
Volatility	28.12 %	43.54 %	41.65 %
Risk-free rate	4.38 %	4.35 %	1.72 %
Dividend assumption	reinvested	reinvested	reinvested
Expected term in years	3	3	3

The Company incurred stock compensation expense of \$1,233 \$1,319 and \$688 \$2,552 for the three and six months ended March 31, 2024 June 30, 2024, respectively, and 2023, \$1,147 and \$1,835 for the three and six months ended June 30, 2023, respectively, related to the grants awarded under the Plan. Compensation expense is included within "General and Administrative" expense in the Company's Condensed Consolidated Statements of Operations.

As of March 31, 2024 June 30, 2024, total unamortized compensation expense related to these awards of approximately \$9.1 million \$8.2 million is expected to be recognized over a weighted average remaining period of 1.7 1.5 years.

Note 8 – Leases

The Company operates as both a lessor and a lessee. As a lessor, the Company is required under ASC Topic 842 to account for leases using an approach that is substantially similar to ASC Topic 840's guidance for operating leases and other leases such as sales-type leases and direct financing leases. In addition, ASC Topic 842 requires lessors to capitalize and amortize only incremental direct leasing costs. As a lessee, the Company is required under the new standard to apply a dual approach, classifying leases, such as ground leases, as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC Topic 842 also requires lessees to record a right of use asset and a lease liability for all leases with an initial term of greater than a year regardless of their classification. The Company has also elected the practical expedient not to recognize right of use assets and lease liabilities for leases with a term of a year or less.

-21-

Table of Contents

Information as Lessor

To generate positive cash flow, as a lessor, the Company leases its facilities to tenants in exchange for fixed monthly payments that cover rent, property taxes, insurance and certain cost recoveries, primarily common area maintenance ("CAM"). The Company's leases were determined to be operating leases and have a portfolio-average-lease-years remaining of approximately 10 years. Payments from the Company's tenants for CAM are considered nonlease components that are separated from lease components and are generally accounted for in accordance with the revenue recognition standard. However, the Company qualified for and elected the practical expedient related to combining the components because the lease component is classified as an operating lease and the timing and pattern of transfer of CAM income, which is not the predominant component, is the same as the lease component, for all asset classes. As such, consideration for CAM is accounted for as part of the overall consideration in the lease. Payments from customers for property taxes and insurance are considered non-components of the lease and therefore no consideration is allocated to them because they do not transfer a good or service to the customer. Fixed contractual payments from the Company's leases are recognized on a straight-line basis over the terms of the respective leases. This means that, with respect to a particular lease, actual amounts billed in accordance with the lease during any given period may be higher or lower than the amount of rental revenue recognized for the period. Straight-line rental revenue is commenced when the tenant assumes control of the leased premises. Accrued straight-line rents receivable represents the amount by which straight-line rental revenue exceeds rents currently billed in accordance with lease agreements.

Some of the Company's leases are subject to annual changes in the Consumer Price Index ("CPI"). Although increases in CPI are not estimated as part of the Company's measurement of straight-line rental revenue, for leases with base rent increases based on CPI, the amount of rent revenue recognized is adjusted in the period the changes in CPI are measured and effective. Additionally, some of the Company's leases have extension options.

-20-

[Table of Contents](#)

Initial direct costs, primarily commissions related to the leasing of our facilities are capitalized when material as incurred. Capitalized leasing costs are amortized on a straight-line basis over the remaining useful life of the respective leases. All other costs to negotiate or arrange a lease are expensed as incurred.

Lease-related receivables, which include accounts receivable and accrued straight-line rents receivable, are reduced for credit losses, if applicable. The Company regularly evaluates the collectability of its lease-related receivables. The Company's evaluation of collectability primarily consists of reviewing past due account balances and considering such factors as the credit quality of our tenant, historical trends of the tenant and changes in tenant payment terms. If the Company's assumptions regarding the collectability of lease-related receivables prove incorrect, the Company could experience credit losses in excess of what was recognized in rental and other revenues.

The Company recognized ~~\$35,069~~ \$34,214 and ~~\$36,199~~ \$69,283 of rental revenue related to operating lease payments for the three and six months ended ~~March 31, 2024~~ June 30, 2024, respectively, and ~~2023~~, \$36,317 and \$72,517 of rental revenue related to operating lease payments for the three and six months ended June 30, 2023, respectively. Of these amounts, \$1,963 and ~~\$2,003~~ \$3,926 relate to variable rental revenue for the three and six months ended ~~March 31, 2024~~ June 30, 2024, respectively, and ~~2023~~, \$1,856 and \$3,859 relate to variable rental revenue for the three and six months ended June 30, 2023, respectively.

The aggregate annual cash to be received by the Company on the noncancelable operating leases related to its portfolio as of ~~March 31, 2024~~ June 30, 2024 is as follows for the subsequent years ended December 31:

2024 (nine months remaining)	\$	85,074	
2024 (six months remaining)			\$ 54,905
2025		105,522	106,662
2026		97,031	100,313
2027		85,748	89,007
2028		75,271	78,861
Thereafter		274,599	287,494
Total	\$	723,245	\$717,242

Information as Lessee

The Company recorded a right of use asset and liability in May 2023 on the commencement date of the lease for its corporate headquarters in Bethesda, Maryland. The Company used a discount rate of approximately 6.5% to record the right of use asset and liability, which represented its incremental borrowing rate at the lease commencement date. Additionally, the Company has seven

-22-

Table of Contents

buildings located on land that is subject to operating ground leases with a weighted average remaining term of approximately 42 years. Rental payments on these leases are adjusted periodically based on either the CPI or on a pre-determined schedule. The monthly payments on a pre-determined schedule are recognized on a straight-line basis over the terms of the respective leases. Changes in the CPI are not estimated as part of our measurement of straight-line rental expense. The Company used a weighted average discount rate of approximately 7.5% to record the right of use assets and liabilities, which was derived, using a portfolio approach, from our assessment of the credit quality of the Company and adjusted to reflect secured borrowing, estimated yield curves and long-term spread adjustments over appropriate tenors. Some of the Company's ground leases contain extension options and, where we determined it was reasonably certain that an extension would occur, they were included in our calculation of the right of use asset and liability. The Company recognized approximately \$55 and \$65 \$110 of ground lease expense during the three and six months ended March 31, 2024 and 2023, June 30, 2024, respectively, of which \$22 \$31 and \$42 \$52 was paid in cash. The Company recognized approximately \$88 and \$153 of ground lease expense during the three and six months ended June 30, 2023, respectively, of which \$39 and \$81 was paid in cash.

-21-

Table of Contents

The following table sets forth the undiscounted cash flows of our scheduled obligations for future lease payments on operating ground leases at March 31, 2024 June 30, 2024, and a reconciliation of those cash flows to the operating lease liability at March 31, 2024 June 30, 2024:

2024 (nine months remaining)	\$	543	
2024 (six months remaining)			\$ 363
2025		740	740
2026		757	757
2027		772	772
2028		794	794
Thereafter		9,657	9,657
Total		13,263	13,083
Discount		(5,428)	(5,376)
Lease liability	\$	7,835	\$ 7,707

Tenant Concentration

During the three six months ended March 31, 2024 June 30, 2024, the Company's rental revenues were derived from 268 tenants leasing 185 184 buildings. During this period there were no tenants with rental revenue that exceeded 10% of the Company's rental revenue.

Note 9 – Commitments and Contingencies

Litigation

The Company is not presently subject to any material litigation nor, to its knowledge, is any material litigation threatened against the Company, which if determined unfavorably to the Company, would have a material adverse effect on the Company's financial position, results of operations, or cash flows.

Environmental Matters

The Company follows a policy of monitoring its properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at its properties, the Company is not currently aware of any environmental liability with respect to its properties that would have a material effect on its financial position, results of operations, or cash flows. Additionally, the Company is not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that management believes would require additional disclosure or the recording of a loss contingency.

-22- -23-

[Table of Contents](#)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our financial statements, including the notes to those financial statements, included elsewhere in this Quarterly Report on Form 10-Q (this "Report"). Some of the statements we make in this section are forward-looking statements within the meaning of the federal securities laws. For a complete discussion of forward-looking statements, see the section below entitled "Special Note Regarding Forward-Looking Statements." Certain risk factors may cause actual results, performance, or achievements to differ materially from those expressed or implied by the following discussion. For a discussion of such risk factors, see Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2023, that was filed with the U.S. Securities and Exchange Commission (the "SEC" or the "Commission") on February 28, 2024. Unless otherwise indicated, all dollar and share amounts in the following discussion are presented in thousands.

Special Note Regarding Forward-Looking Statements

This Report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")). In particular, statements pertaining to our trends, liquidity, capital resources, and the healthcare industry and the healthcare real estate markets and opportunity, among others, contain forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology including, but not limited to, "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates" or "anticipates" or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

- difficulties in identifying healthcare facilities to acquire (due to increased cost of capital, competition or otherwise) and completing such acquisitions;
- defaults on or non-renewal of leases by tenants;
- our ability to collect rents;
- increases in interest rates and increased operating costs;
- macroeconomic and geopolitical factors, including, but not limited to, inflationary pressures, interest rate volatility, distress in the banking sector, global supply chain disruptions and ongoing geopolitical conflicts and war;
- changes in current healthcare and healthcare real estate trends and costs, including wage inflation;
- an epidemic or pandemic (such as the COVID-19 pandemic), and the measures that international, federal, state and local governments, agencies, law enforcement and/or health authorities implement to address it;

- our ability to satisfy the covenants in our existing and any future debt agreements;
- decreased rental rates or increased vacancy rates, including expected rent levels on acquired properties;
- adverse economic or real estate conditions or developments, either nationally or in the markets in which our facilities are located;
- our failure to generate sufficient cash flows to service our outstanding obligations;
- our ability to satisfy our short and long-term liquidity requirements;

-23- -24-

[Table of Contents](#)

- our ability to deploy the debt and equity capital we raise;
- our ability to hedge our interest rate risk;
- our ability to raise additional equity and debt capital on terms that are attractive or at all;
- our ability to make distributions on shares of our common and preferred stock or to redeem our preferred stock;
- expectations regarding the timing and/or completion of any acquisition;
- expectations regarding the timing and/or completion of dispositions, and the expected use of proceeds therefrom;
- general volatility of the market price of our common and preferred stock;
- changes in our business or our investment or financing strategy;
- our dependence upon key personnel, whose continued service is not guaranteed;
- our ability to identify, hire and retain highly qualified personnel in the future;
- the degree and nature of our competition;
- changes in healthcare laws, governmental regulations, tax laws and similar matters;
- changes in expected trends in Medicare, Medicaid and commercial insurance reimbursement trends;
- competition for investment opportunities;
- our failure to successfully integrate acquired healthcare facilities;
- our expected capital and tenant improvement expenditures;
- changes in accounting policies generally accepted in the United States of America ("GAAP");
- lack of, or insufficient amounts of, insurance;
- other factors affecting the real estate industry generally;
- changes in the tax treatment of our distributions;
- our failure to maintain our qualification as a real estate investment trust ("REIT") for U.S. federal income tax purposes;
- our ability to qualify for the safe harbor from the 100% prohibited transactions tax under the REIT rules with respect to our property dispositions; and
- limitations imposed on our business due to, and our ability to satisfy, complex rules relating to REIT qualification for U.S. federal income tax purposes.

See Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023 for further discussion of these and other risks, as well as the risks, uncertainties and other factors discussed in this Report and identified in other documents we may file with the SEC from time to time. You should carefully consider these risks before making any investment decisions in our company. New risks and uncertainties may also emerge from time to time that could materially and adversely affect us. While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or

methods, future events or other changes after the date of this Report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements.

-24- -25-

[Table of Contents](#)

Objective of MD&A

Management's Discussion and Analysis ("MD&A") is a narrative explanation of the financial statements and other statistical data that we believe will enhance a reader's understanding of our financial condition, changes in financial condition and results of operations.

The objectives of MD&A are:

- To provide a narrative explanation of our financial statements that enables investors to see the Company from management's perspective;
- To enhance the overall financial disclosure and provide the context within which financial information should be analyzed; and
- To provide information about the quality of, and potential variability of, our earnings and cash flow so that investors can ascertain the likelihood that past performance is indicative of future performance.

Overview

Global Medical REIT Inc. (the "Company," "us," "we," or "our") is a Maryland corporation and internally managed REIT that owns and acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. We hold our facilities and conduct our operations through a Delaware limited partnership subsidiary, Global Medical REIT L.P. (the "Operating Partnership"). Our wholly owned subsidiary, Global Medical REIT GP LLC, is the sole general partner of our Operating Partnership and, as of March 31, 2024 June 30, 2024, we owned 92.44% 92.36% of the outstanding common operating partnership units ("OP Units") of our Operating Partnership, with an aggregate of 7.56% 7.64% of the Operating Partnership owned by holders of long-term incentive plan units ("LTIP Units") and third-party limited partners who contributed properties or services to the Operating Partnership in exchange for OP Units.

Our revenues are derived from the rental and operating expense reimbursement payments we receive from our tenants, and most of our leases are medium to long-term triple net leases with contractual rent escalation provisions. Our primary expenses are depreciation, interest, and general and administrative expenses. We finance our acquisitions with a mixture of debt and equity primarily from our cash from operations, borrowings under our Second Amended and Restated Credit Facility (the "Credit Facility"), and stock issuances.

Business Overview and Strategy

Our business strategy is to invest in healthcare properties that provide an attractive rate of return relative to our cost of capital and are operated by profitable physician groups, regional or national healthcare systems or combinations thereof. We believe this strategy allows us to attain our goals of providing stockholders with (i) reliable dividends and (ii) stock price appreciation. To implement this strategy, we seek to invest:

- in off-campus medical office outpatient buildings and other de-centralized components of the healthcare delivery system because we believe that healthcare delivery trends in the U.S. are increasingly moving away from centralized hospital locations;
- in small to mid-sized healthcare facilities located in secondary markets and suburbs of primary markets and that provide services needed for an aging population, such as cardiovascular treatment, rehabilitation, eye surgery, gastroenterology, oncology treatment and orthopedics. We believe these facilities and markets are typically overlooked by larger REITs and other healthcare investors but contain tenant credit profiles that are like those of larger, more expensive facilities in primary markets; and
- to a lesser extent, in opportunistic acquisitions, including (i) certain acute-care hospitals and long-term acute care facilities (LTACs) that we believe provide premium, risk-adjusted returns, (ii) health system corporate office and administrative buildings, which we believe will help us develop relationships with larger health systems and (iii) behavioral and mental health facilities that are operated by national or regional operators and are located in markets that demonstrate a need for such services.

-25-

Most of our healthcare facilities are leased to single-tenants under triple-net leases. As we continue to grow our portfolio and the competition for single-tenant, triple-net leased properties has intensified, we have added to our portfolio some multi-tenant properties with gross lease or modified gross lease structures.

Corporate Sustainability and Social Responsibility

Our business values integrate environmental sustainability, social responsibility, and strong governance practices throughout our Company.

Our Board of Directors (the “Board”) continues to lead our environmental, social and governance (“ESG”) efforts through a standing ESG committee. The primary purpose of the ESG committee is to assist the Board in fulfilling its responsibilities to provide oversight and support of our commitment to ESG matters by overseeing: (1) our general ESG strategy and policies as set by our management, (2) communications with our employees, investors, and other stakeholders with respect to ESG matters, (3) developments relating to, and improving our understanding of, ESG matters, (4) our compliance with certain ESG-related legal and regulatory requirements, and (5) coordination with our other Board committees on ESG matters of common import.

In June 2023, 2024, we released our second third Corporate Social Responsibility Report, which detailed our progress and areas of focus in the ESG realm. The contents of our Corporate Social Responsibility Report are not incorporated by reference into this Report or in any other report or document we file with the SEC.

Our commitment to employee engagement remains a high-priority, as we continue to make accommodations for health, safety, and work-life balance, including at our headquarters which is LEED platinum certified and includes a fitness center, café and roof-top lounge.

Climate Change Risk

We take climate change and the risks associated with climate change seriously, including both physical and transitional risks. We utilize software to help us identify and measure the potential climate risk exposure for our properties. The software analysis summarizes the climate change-related risks, groups them by onset potential and identifies opportunities for risk mitigation. We prioritize energy efficiency and sustainability when evaluating investment opportunities and have begun to monitor our portfolio for climate risk factors. We utilize utility and energy audits that are performed by third-party engineering consultants during the due diligence phase of our acquisitions. The energy consumption data that we collect is used to assess our facilities' carbon emission levels. Capturing and tracking this information may help inform future mitigation and remediation efforts when possible. To that end, we continue to explore ways to mitigate climate risk, should it be present, in our acquisition strategy, as well as ways to contribute to the reduction of climate impact through proactive asset management that looks for ways to incorporate renewable energy resources and energy utilization reduction.

We stand with our communities, tenants, and stockholders in supporting meaningful solutions that address this global challenge and contribute to the sustainability of our business objectives.

Impact of Increased Interest Rates and Inflation

After many years of low inflation, the U.S. inflation rate increased substantially during 2022 and remained elevated during 2023 and into the first quarter of 2024. In response to elevated inflation, the U.S. Federal Reserve (the “Fed”) increased the target range for the Federal Funds Rate from 0.25% – 0.50% in the first quarter of 2022 to 5.25% – 5.50% as of May 2024. Many market participants had anticipated that the high trajectory of interest rates during 2022 and throughout 2023 would lead to an economic recession towards the end of 2023 that would have caused the Fed to begin lowering the Federal Funds Rate. However, certain components of the U.S. economy have outperformed expectations and inflation continues to remain higher than the Fed's target rate, which has caused the Fed to take a “wait-and-see” approach to monetary policy rather than beginning a process of lowering the Federal Funds Rate. The increase in the Federal Funds Rate, along with other actions taken by the Fed, had a ripple effect on other benchmark interest rates, including one-month term Secured Overnight Financing Rate (“SOFR”), which is the reference rate for our indebtedness under the Credit Facility. During the first quarter half of 2024, SOFR remained elevated and only decreased moderately from 5.40% at the beginning of the quarter year to 5.34% 5.33% at quarter end, the end of the second

-26- -27-

Additionally, as most of our leases are triple-net leases, we are somewhat insulated from the effects of inflation on our operating expenses. However, due to the longer-term nature of our leases, we are not able to quickly increase rents to offset fully the effects of increased interest rates and inflation on our interest expense and other costs. Also, we may not be able to renew expiring leases at lease rates that reflect increases in inflation.

The COVID-19 epidemic affected the healthcare industry in many ways. Many stories exist about U.S. healthcare workers, especially nurses, experiencing burnout due to the length and severity of the epidemic, and this has caused many nurses and other medical professionals to switch jobs within the medical profession or quit their professions altogether. This phenomenon has led to material increases in labor costs for healthcare systems, especially hospital systems, as some employers have had to rely on higher costing contract nursing labor to sustain their businesses. Although reliance on contract nursing and overall healthcare wage inflation may moderate during 2024, the overall increase in healthcare labor costs remains. Whether enhanced technology and cost-saving measures and increased reimbursements from payors will help offset these costs remains to be seen.

The following table summarizes the primary changes in our business and operations during the periods presented.

Three Months Ended March 31,		Three Months Ended		Six Months Ended	
		June 30,		June 30,	
2024	2023	2024	2023	2024	2023

(in thousands, except per share and unit amounts)

(in thousands, except per share and unit amounts)

Rental revenue	\$	35,069	\$	36,199	\$34,214	\$36,317	\$69,283	\$72,517
Depreciation and amortization expense	\$	14,084	\$	14,889	\$13,993	\$14,805	\$28,078	\$29,694
Interest expense	\$	6,890	\$	8,271	\$ 6,992	\$ 8,468	\$13,883	\$16,739
General and administrative expense	\$	4,446	\$	3,804	\$ 4,589	\$ 4,462	\$ 9,035	\$ 8,266
Gain on sale of investment property	\$	—	\$	485				
(Loss) gain on sale of investment properties					\$ (3,383)	\$12,786	\$ (3,383)	\$13,271
Net income attributable to common stockholders per share	\$	0.01	\$	0.01				
FFO per share and unit ⁽¹⁾	\$	0.21	\$	0.22				
AFFO per share and unit ⁽¹⁾	\$	0.23	\$	0.23				

Net (loss) income attributable to common stockholders per share				\$ (0.05)	\$ 0.18	\$ (0.04)	\$ 0.19
FFO attributable to common stockholders and noncontrolling interest per share and unit ⁽¹⁾				\$ 0.20	\$ 0.21	\$ 0.41	\$ 0.43
AFFO attributable to common stockholders and noncontrolling interest per share and unit ⁽¹⁾				\$ 0.22	\$ 0.23	\$ 0.46	\$ 0.45
Dividends per share of common stock	\$ 0.21	\$ 0.21		\$ 0.21	\$ 0.21	\$ 0.42	\$ 0.42
Weighted average common stock outstanding	65,573	65,525		65,588	65,544	65,580	65,534
Weighted average OP Units outstanding	2,244	1,667		2,244	2,143	2,244	1,907
Weighted average LTIP Units outstanding	2,940	2,638		3,150	2,747	3,020	2,678
Total weighted average shares and units outstanding	70,757	69,830		70,982	70,434	70,844	70,119

⁽¹⁾ See “—Non-GAAP Financial Measures,” for a description of our non-GAAP financial measures and a reconciliation of our non-GAAP financial measures.

As of		As of	
March 31,	December 31,	June 30,	December 31,
2024	2023	2024	2023

	(dollars in thousands)		(dollars in thousands)	
Investment in real estate, gross	\$ 1,428,161	\$ 1,426,969	\$ 1,415,288	\$ 1,426,969
Total debt, net	\$ 617,764	\$ 611,232	\$ 613,670	\$ 611,232
Weighted average interest rate	3.85 %	3.83 %	3.89 %	3.83 %
Total equity (including noncontrolling interest)	\$ 597,098	\$ 605,814	\$ 578,372	\$ 605,814
Net leasable square feet	4,750,640	4,748,626	4,704,870	4,748,626

-27- -28-

[Table of Contents](#)

Our Properties

As of **March 31, 2024** **June 30, 2024**, our portfolio consisted of gross investment in real estate of \$1.4 billion, with an aggregate of **4.8 million** **4.7 million** leasable square feet and an aggregate **\$110.5 million** **\$106.0 million** of annualized base rent. **We completed no acquisitions during the six months ended June 30, 2024.**

Properties Under Contract to Acquire and Completed Acquisitions Subsequent to June 30, 2024

In May 2024, **the Company** **we** entered into a purchase agreement to acquire a 15-property portfolio (the “15-property portfolio”) of outpatient medical real **estate** **estate**. In July 2024 we completed the acquisition of five properties in the 15-property portfolio encompassing 94,494 leasable square feet for an aggregate purchase price of **\$81.3 million** **\$30.8 million** with aggregate annualized base rent of \$2.5 million. **The properties are fully occupied and leased under triple-net or absolute triple-net leases.**

The Company expects **We expect** to complete **this** **the** acquisition in two tranches, with of the first tranche (approximately \$30 million - \$35 million) **closing** **remaining 10 properties** in the **third quarter** **15-property portfolio**, with an aggregate purchase price of 2024 and the remainder closing in \$49.5 million, **during** the fourth quarter of 2024. The Company's obligation to close the acquisition **of the remaining 10 properties in the 15-property portfolio** is subject to

certain customary terms and conditions, including due diligence reviews. Accordingly, there is no assurance that **the Company** **we** will close this acquisition on a timely basis, or at all.

Completed Property Disposition

In June 2024, we sold an in-patient rehabilitation facility located in Mishawaka, Indiana, receiving gross proceeds of \$8.1 million, resulting in a loss of \$3.4 million. The net proceeds from this disposition were used to pay down outstanding borrowings from the Credit Facility.

Completed Property Disposition Subsequent to June 30, 2024

In July 2024, we sold a medical office building located in Panama City, Florida receiving gross proceeds of \$11.0 million. This property had a net book value of approximately \$8.9 million at the time of sale.

Capital Raising Activity

In January 2024, the Company and the Operating Partnership implemented a \$300 million "at-the-market" equity offering program, pursuant to which we may offer and sell (including through forward sales), from time to time, shares of our common stock (the "2024 ATM Program"). No shares were sold under the 2024 ATM Program during the **three** **six** months ended **March 31, 2024** **June 30, 2024**.

Debt Activity

During the **three** **six** months ended **March 31, 2024** **June 30, 2024**, we borrowed **\$14.0 million** **\$38.5 million** under the Credit Facility and repaid **\$7.8 million** **\$25.9 million**, for a net amount borrowed of **\$6.2 million** **\$12.6 million**. During the **three** **six** months ended **March 31, 2023** **June 30, 2023**, we borrowed **\$12.6 million** **\$24.6 million** under the Credit Facility and repaid **\$14.8 million** **\$94.2 million**, for a net amount repaid of **\$2.2 million** **\$69.6 million**. As of **March 31, 2024** **June 30, 2024**, the net outstanding Credit Facility balance was **\$592.1 million** **\$599.0 million** and as of **May 6, 2024** **August 5, 2024**, we had unutilized borrowing capacity under the Revolver of **\$290 million** **\$261 million**.

Recent Developments

Chapter 11 Reorganization Filing of Steward Health Care

On May 6, 2024, one of the Company's tenants, Steward Health Care ("Steward"), announced that it filed for Chapter 11 bankruptcy reorganization. As of March 31, 2024, Steward represented 2.8% of the Company's annualized base rent, primarily in one facility located in Beaumont, Texas (the "Beaumont Facility"). Steward was current in its rental payments through February 2024 and as of March 31, 2024, the Company's receivable balance from Steward was \$0.5 million, including \$0.2 million of deferred rent. The Company was actively pursuing re-leasing opportunities at the Beaumont Facility prior to the Steward bankruptcy announcement and is optimistic about its long term prospects at this location. There can be no assurances that the Company will receive any amounts owed to it by Steward or that the Company will be able to successfully re-lease the Beaumont Facility.

Trends Which May Influence Our Results of Operations

We believe the following trends may positively impact our results of operations:

- *An aging population.* According to the 2020 U.S. Census, the nation's 65-and-older population has grown rapidly since 2010, driven by the aging of Baby Boomers born between 1946 and 1964. The 65-and-older population grew by over a third during the past decade, and by 3.2% from 2018 to 2019. We believe this segment of the U.S. population will utilize many of the services provided at our healthcare facilities such as orthopedics, cardiac, gastroenterology and rehabilitation.
- *A continuing shift towards outpatient care.* According to the American Hospital Association, patients are demanding more outpatient operations. We believe this shift in patient preference from inpatient to outpatient facilities will benefit our tenants as most of our properties consist of outpatient facilities.

- *Physician practice group and hospital consolidation.* We believe the trend towards physician group consolidation will serve to strengthen the credit quality of our tenants if our tenants merge or are consolidated with larger health systems.

We believe the following trends may negatively impact our results of operations:

- *Fed's "wait-and-see" approach could cause interest rates to remain elevated for longer than previously expected.* Market ~~Although market~~ reaction to the Fed's commentary after its ~~May~~ July 2024 meeting, where it maintained the target range for the Federal Funds Rate at 5.25% to 5.50%, indicated that the Fed ~~does not plan to cut interest rates until it has more time to analyze whether previous interest rate increases have had the desired effect on inflation, which could result in continued elevated~~ ~~may begin cutting~~ interest rates in 2024, ~~there is no guarantee that interest rate cuts will begin in 2024, especially if inflation is not longer reduced to the Fed's target level.~~ Although term SOFR, which is the reference rate for our floating rate debt, is expected to decrease during 2024 and 2025, any action or inaction by the Fed in the coming months could affect the timing and amounts of such decreases.

Continued elevated interest rates have contributed to a continued lull in the common stock prices of many REITs, including the price of the Company's common stock. A continued low stock price and elevated interest rates have caused the Company's cost of capital to remain elevated, which, in turn, has significantly reduced the ability to acquire assets that meet the Company's investment requirements.

- *Healthcare Wage Inflation.* The COVID-19 epidemic affected the healthcare industry in many ways. Many stories exist about U.S. healthcare workers, especially nurses, experiencing burnout due to the length and severity of the epidemic, and this has caused many nurses and other medical professionals to switch jobs within the medical profession or quit their professions altogether. This phenomenon has led to material increases in labor costs for healthcare systems, especially hospital systems, as some employers have had to rely on higher costing contract nursing labor to sustain their businesses. Although reliance on contract nursing and overall healthcare wage inflation may moderate during 2024, the overall increase in healthcare labor costs remains. Whether enhanced technology and cost-saving measures and increased reimbursements from payors will help offset these costs remains to be seen.
- *Changes in third party reimbursement methods and policies.* The price of healthcare services has been increasing, and, as a result, we believe that third-party payors, such as Medicare and commercial insurance companies, will continue to scrutinize and reduce the types of healthcare services eligible for, and the amounts of, reimbursement under their health insurance plans. Additionally, many employer-based insurance plans continue to increase the percentage of insurance premiums for which covered individuals are responsible, which makes healthcare services more expensive for individuals. These trends were exacerbated by the COVID-19 epidemic, as medical expenditures increased significantly during the epidemic and have not yet returned to pre-COVID-19 levels. If these trends continue, our tenants' businesses will continue to be negatively affected, which may impact their ability to pay rent to us.

Critical Accounting Estimates

The preparation of financial statements in conformity with GAAP requires our management to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on February 28, 2024, for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our condensed consolidated financial statements included in Part I, Item 1 of this Report.

Consolidated Results of Operations

The major factors that resulted in differences in our financial results for the three ~~and six~~ months ended ~~March 31, 2024~~ June 30, 2024, compared to the same ~~period periods~~ in 2023, were lower interest rates due to lower leverage and the impact of our interest rate swaps, lower average borrowings, ~~a loss on a disposition transaction that was completed in June 2024,~~ and the impact resulting from three property disposition ~~transactions that were completed during 2023. Our total investment~~

-29- -30-

[Table of Contents](#)

transactions that were completed during 2023. Our total investment in real estate, net of accumulated depreciation and amortization, was \$1.1 billion as of June 30, 2024 compared to \$1.2 billion as of March 31, 2024 compared to \$1.3 billion as of March 31, 2023 June 30, 2023.

Three Months Ended March 31, 2024 June 30, 2024 Compared to Three Months Ended March 31, 2023 June 30, 2023

	Three Months Ended March 31,			Three Months Ended June 30,		
	2024	2023	\$ Change	2024	2023	\$ Change
	(in thousands)			(in thousands)		
Revenue						
Rental revenue	\$ 35,069	\$ 36,199	\$ (1,130)	\$ 34,214	\$ 36,317	\$ (2,103)
Other income	49	31	18	27	34	(7)
Total revenue	35,118	36,230	(1,112)	34,241	36,351	(2,110)
Expenses						
General and administrative	4,446	3,804	642	4,589	4,462	127
Operating expenses	7,384	7,536	(152)	7,236	7,223	13
Depreciation expense	10,113	10,494	(381)	10,127	10,468	(341)
Amortization expense	3,971	4,395	(424)	3,866	4,337	(471)
Interest expense	6,890	8,271	(1,381)	6,992	8,468	(1,476)
Preacquisition expense	—	42	(42)	—	2	(2)
Total expenses	32,804	34,542	(1,738)	32,810	34,960	(2,150)
Income before gain from sale of investment property	2,314	1,688	626			
Gain on sale of investment property	—	485	(485)			
Net income	\$ 2,314	\$ 2,173	\$ 141			
Income before (loss) gain from sale of investment properties				1,431	1,391	40
(Loss) gain on sale of investment properties				(3,383)	12,786	(16,169)
Net (loss) income				\$ (1,952)	\$ 14,177	\$ (16,129)

Revenue

Total Revenue

Total revenue for the three months ended March 31, 2024 June 30, 2024 was \$35.1 million \$34.2 million, compared to \$36.2 million \$36.4 million for the same period in 2023, a decrease of \$1.1 million \$2.2 million. The decrease primarily resulted from the impact of three property disposition transactions during 2023. Within that decrease, \$5.0 million \$4.9 million in revenue was recognized from net lease expense recoveries during the three months ended March 31, 2024 June 30, 2024, compared to \$5.2 million \$5.0 million for the same period in 2023. Additionally, the current period includes the recognition of reserves for \$0.8 million of rent and the write-off of \$0.1 million of deferred rent.

Expenses

General and Administrative

General and administrative expenses for the three months ended March 31, 2024 June 30, 2024 were \$4.4 million \$4.6 million, compared to \$3.8 million \$4.5 million for the same period in 2023, an increase of \$0.6 million \$0.1 million. The increase resulted from an increase in non-cash LTIP compensation expense, which was \$1.2 million \$1.3 million for the three months ended March 31, 2024 June 30, 2024, compared to \$0.7 million \$1.1 million for the same period in 2023, and an increase partially offset by a decrease in cash compensation and general corporate expenses.

Operating Expenses

Operating expenses for the three months ended March 31, 2024 June 30, 2024 and 2023 were \$7.4 million, compared to \$7.5 million for the same period \$7.2 million. Included in 2023, a decrease of \$0.1 million. The decrease resulted primarily from \$5.0 million these amounts were \$4.9 million of recoverable property operating expenses incurred during the three months ended March 31, 2024 June 30, 2024, compared to \$5.2 million \$5.0 million for the same period in 2023. In addition, our operating expenses included \$1.5 million \$0.9 million of property operating expenses from gross leases for the three months ended March 31, 2024 and June 30, 2024, compared to \$1.6 million for the same period in 2023.

-31-

[Table of Contents](#)

Depreciation Expense

Depreciation expense for the three months ended March 31, 2024 June 30, 2024 was \$10.1 million, compared to \$10.5 million for the same period in 2023, a decrease of \$0.4 million. The decrease primarily resulted from the impact of three property disposition transactions during 2023.

-30-

[Table of Contents](#)

Amortization Expense

Amortization expense for the three months ended March 31, 2024 June 30, 2024 was \$4.0 million \$3.9 million, compared to \$4.4 million \$4.3 million for the same period in 2023, a decrease of \$0.4 million. The decrease primarily resulted from the impact of three property disposition transactions during 2023.

Interest Expense

Interest expense for the three months ended March 31, 2024 June 30, 2024 was \$6.9 million \$7.0 million, compared to \$8.3 million \$8.5 million for the same period in 2023, a decrease of \$1.4 million \$1.5 million. This decrease was due to lower interest rates and lower average borrowings during the three months ended March 31, 2024 June 30, 2024, compared to the same period in 2023.

The weighted average interest rate of our debt for the three months ended March 31, 2024 June 30, 2024 was 3.90% 3.93% compared to 4.27% 4.39% for the same period in 2023. Additionally, the weighted average interest rate and term of our debt was 3.85% 3.89% and 2.7 2.5 years at March 31, 2024 June 30, 2024.

Income Before (Loss) Gain on Sale of Investment Property Properties

Income before (loss) gain on sale of investment properties for the three months ended June 30, 2024 and 2023 was \$1.4 million.

(Loss) Gain on Sale of Investment Properties

During the three months ended June 30, 2024, we sold an in-patient rehabilitation facility located in Mishawaka, Indiana receiving gross proceeds of \$8.1 million, resulting in a loss of \$3.4 million. During the three months ended June 30, 2023, we sold a portfolio of four medical office buildings located in Oklahoma City, Oklahoma receiving gross proceeds of \$66.0 million, resulting in a gain of \$12.8 million.

Net (Loss) Income

Net loss for the three months ended June 30, 2024 was \$2.0 million, compared to net income of \$14.2 million for the same period in 2023.

-32-

Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023

	Six Months Ended June 30,		\$ Change
	2024	2023	
	(in thousands)		
Revenue			
Rental revenue	\$ 69,283	\$ 72,517	\$ (3,234)
Other income	77	64	13
Total revenue	69,360	72,581	(3,221)
Expenses			
General and administrative	9,035	8,266	769
Operating expenses	14,619	14,759	(140)
Depreciation expense	20,240	20,962	(722)
Amortization expense	7,838	8,732	(894)
Interest expense	13,883	16,739	(2,856)
Preacquisition expense	—	44	(44)
Total expenses	65,615	69,502	(3,887)
Income before (loss) gain from sale of investment properties	3,745	3,079	666
(Loss) gain on sale of investment properties	(3,383)	13,271	(16,654)
Net income	\$ 362	\$ 16,350	\$ (15,988)

Revenue
Total Revenue

Total revenue for the six months ended June 30, 2024 was \$69.4 million, compared to \$72.6 million for the same period in 2023, a decrease of \$3.2 million. The decrease primarily resulted from the impact of three property disposition transactions during 2023. Within that decrease, \$9.9 million in revenue was recognized from net lease expense recoveries during the six months ended June 30, 2024, compared to \$10.2 million for the same period in 2023. Additionally, the current period includes the recognition of reserves for \$0.8 million of rent and the write-off of \$0.1 million of deferred rent.

Expenses
General and Administrative

General and administrative expenses for the six months ended June 30, 2024 were \$9.0 million, compared to \$8.3 million for the same period in 2023, an increase of \$0.7 million. The increase resulted from an increase in non-cash LTIP compensation expense, which was \$2.6 million for the six months ended June 30, 2024, compared to \$1.8 million for the same period in 2023, partially offset by a decrease in general corporate expenses.

Operating Expenses

Operating expenses for the six months ended June 30, 2024 were \$14.6 million, compared to \$14.8 million for the same period in 2023, a decrease of \$0.2 million. The decrease resulted primarily from \$9.9 million of recoverable property operating expenses incurred during the six months ended June 30, 2024, compared to \$10.2 million for the same period in 2023. In addition, our operating expenses included \$2.4 million of property operating expenses from gross leases for the six months ended June 30, 2024, compared to \$3.1 million for the same period in 2023.

Depreciation Expense

Depreciation expense for the six months ended June 30, 2024 was \$20.2 million, compared to \$21.0 million for the same period in 2023, a decrease of \$0.8 million. The decrease primarily resulted from the impact of three property disposition transactions during 2023.

Amortization Expense

Amortization expense for the six months ended June 30, 2024 was \$7.8 million, compared to \$8.7 million for the same period in 2023, a decrease of \$0.9 million. The decrease primarily resulted from the impact of three property disposition transactions during 2023.

Interest Expense

Interest expense for the six months ended June 30, 2024 was \$13.9 million, compared to \$16.7 million for the same period in 2023, a decrease of \$2.8 million. This decrease was due to lower interest rates and lower average borrowings during the six months ended June 30, 2024, compared to the same period in 2023.

The weighted average interest rate of our debt for the six months ended June 30, 2024 was 3.92% compared to 4.32% for the same period in 2023. Additionally, the weighted average interest rate and term of our debt was 3.89% and 2.5 years at June 30, 2024.

Income Before (Loss) Gain on Sale of Investment Properties

Income before gain on sale of investment property properties for the three six months ended March 31, 2024 June 30, 2024 was \$2.3 million \$3.7 million, compared to \$1.7 million \$3.1 million for the same period in 2023, an increase of \$0.6 million.

(Loss) Gain on Sale of Investment Property Properties

During the three six months ended March 31, 2024 June 30, 2024, we had no property sales. sold an in-patient rehabilitation facility located in Mishawaka, Indiana receiving gross proceeds of \$8.1 million, resulting in a loss of \$3.4 million. During the three six months ended March 31, 2023 June 30, 2023, we sold a portfolio of four medical office buildings located in Oklahoma City, Oklahoma receiving gross proceeds of \$66.0 million, resulting in a gain of \$12.8 million and we sold a medical office building located in Jacksonville, Florida receiving gross proceeds of \$4.4 million, resulting in a gain of approximately \$0.5 million.

Net Income

Net income for the three six months ended March 31, 2024 June 30, 2024 was \$2.3 million \$0.4 million, compared to \$2.2 million \$16.4 million for the same period in 2023, an increase a decrease of \$0.1 million \$16.0 million.

Assets and Liabilities

As of March 31, 2024 June 30, 2024 and December 31, 2023, our principal assets consisted of investments in real estate, net, of \$1.1 billion and \$1.2 billion, respectively. We completed no acquisitions or and completed one property sales sale during the three six months ended March 31, 2024 June 30, 2024. Our liquid assets consisted primarily of cash and cash equivalents and restricted cash of \$7.8 million and \$6.7 million, as of March 31, 2024 June 30, 2024 and December 31, 2023, respectively.

The increase in our cash and cash equivalents and restricted cash balances to \$7.8 million as of March 31, 2024 June 30, 2024, compared to \$6.7 million as of December 31, 2023, was primarily due to net borrowings on our Credit Facility and net cash provided by operating activities, partially offset by funds used to pay dividends to our common and preferred stockholders and holders of OP Units and LTIP Units and funds used for capital expenditures on existing real estate investments and leasing commissions.

The increase in our total liabilities to \$666.5 million \$662.8 million as of March 31, 2024 June 30, 2024 compared to \$661.9 million as of December 31, 2023, was primarily the result of higher net borrowings outstanding on our Credit Facility, partially offset by a lower notes payable balance outstanding.

Liquidity and Capital Resources

General

Our short-term (up to 12 months) liquidity requirements include:

- Interest expense and scheduled principal payments on outstanding indebtedness, including the payment of the approximately \$11 million outstanding principal balance on the Dumfries loan that matures in June 2024; indebtedness;

-31-

[Table of Contents](#)

- General and administrative expenses;
- Property operating expenses;
- Property acquisitions;
- Distributions on our common and preferred stock and OP Units and LTIP Units; and
- Capital and tenant improvements and leasing costs.

In 2024, we are contractually obligated to pay, or have capital commitments for, principal and interest payments on our outstanding debt and ground and operating lease expenses. In addition, if we decide to redeem our preferred stock in full, we would have to pay the liquidation preference of \$77.6 million plus accrued dividends, fees and expenses.

Our long-term (beyond 12 months) liquidity requirements consist primarily of funds necessary to pay for acquisitions, capital and tenant improvements and leasing costs at our properties, scheduled debt maturities, general and administrative expenses, operating expenses, and distributions. Beyond 2024, we are contractually obligated to pay, or have capital commitments for, principal and interest payments on our outstanding debt and ground and operating lease expenses.

We expect to satisfy our short and long-term liquidity needs through various internal and external sources, including cash flow from operations, debt financing, sales of additional equity securities, the issuance of OP Units in connection with acquisitions of additional properties, proceeds from select property dispositions and recapitalization transactions.

Internal Sources of Liquidity

Our primary internal sources of liquidity include cash flow from operations and proceeds from select property dispositions and recapitalization transactions.

External Sources of Liquidity

Our primary external sources of liquidity include net proceeds received from equity issuances, including the issuance of OP Units in connection with acquisitions of additional properties, and debt financing, including borrowings under our Credit Facility and secured term loans.

Equity Issuances

In January 2024, the Company and the Operating Partnership implemented the 2024 ATM Program, pursuant to which we may offer and sell (including through forward sales), from time to time, shares of our common stock. No shares were sold under the 2024 ATM Program during the three six months ended March 31, 2024 June 30, 2024 or from April 1, 2024 July 1, 2024 through May 6, 2024 August 5, 2024.

Debt Financing

Credit Facility. Our Credit Facility consists of (i) the \$350 million Term Loan A, (ii) the \$150 million Term Loan B, and (iii) the \$400 million Revolver. The Credit Facility also contains a \$500 million accordion feature. As of May 6, 2024 August 5, 2024, we had unutilized borrowing capacity under the Credit Facility of \$290 million \$261 million.

-35-

[Table of Contents](#)

The Credit Facility is an unsecured facility with a term of (i) four years (beginning on August 1, 2022) for the Revolver (subject to two, six-month extension options), (ii) five years for Term Loan A (beginning on its origination date of May 3, 2021), and (iii) five years and six months (beginning on August 1, 2022) for Term Loan B.

We are subject to a number of financial covenants under the Credit Facility, including, among other things, the following as of the end of each fiscal quarter, (i) a maximum consolidated unsecured leverage ratio of less than 60%, (ii) a maximum consolidated secured leverage ratio of less than 30%, (iii) a maximum consolidated secured recourse leverage ratio of less than 10%, (iv) a minimum fixed charge coverage ratio of 1.50:1.00, (v) a minimum unsecured interest coverage ratio of 1.50:1.00, (vi) a maximum consolidated leverage ratio of less than 60%, and (vii) a minimum net worth of \$573 million plus 75% of all net proceeds raised through equity

-32-

[Table of Contents](#)

offerings subsequent to March 31, 2022. As of **March 31, 2024** **June 30, 2024**, management believed it complied with all of the financial and non-financial covenants contained in the Credit Facility.

Other Fixed Debt. We have **\$25.7 million** **\$14.7 million** in gross notes payable as of **March 31, 2024** **June 30, 2024**. This debt is comprised of **three two** instruments.

Hedging Instruments. We have ten interest rate swaps and three forward-starting interest rate swaps that are used to manage our interest rate risk. A description of these swaps is below:

Term Loan A Swaps

As of **March 31, 2024** **June 30, 2024**, six of our interest rate swaps related to Term Loan A. The combined notional value of these swaps is \$350 million, with \$200 million of the swaps maturing in August 2024 and the remaining \$150 million maturing in April 2026. In addition, we have three forward starting interest rate swaps with a combined notional value of \$200 million, each with a maturity date of April 2026, that will become effective on the August 2024 maturity date of the existing swaps. Currently, the Term Loan A swaps fix the SOFR component of Term Loan A at a rate of 1.50% through August 2024. From August 2024 to April 2026 the SOFR component of Term Loan A will be fixed at 1.36%.

Term Loan B Swaps

As of **March 31, 2024** **June 30, 2024**, four of our interest rate swaps related to Term Loan B with a combined notional value of \$150 million that fix the SOFR component on Term Loan B through January 2028 at 2.54%.

Total Fixed Debt. Our fixed debt totaled **\$525.7 million** **\$514.7 million** on a gross basis at **March 31, 2024** **June 30, 2024**, with a weighted average interest rate of **3.31%** **3.28%** based on our interest rate swaps and at current leverage. The weighted average maturity of our fixed debt was **2.6** **2.4** years at **March 31, 2024** **June 30, 2024**. Due to our forward swap structures, the weighted average interest rate on fixed debt outstanding as of **March 31, 2024** **June 30, 2024** is expected to improve over the next two years.

Cash Flow Information

Net cash provided by operating activities for the **three six** months ended **March 31, 2024** **June 30, 2024** was **\$14.3 million** **\$33.2 million**, compared to **\$15.8 million** **\$33.6 million** for the same period in 2023. During the 2024 period **net income was lower**, non-cash depreciation and amortization expenses were lower, **and tenant receivables increased**, and **certain liabilities decreased**, **deferred assets were higher**, partially offset by **a loss on the sale of an investment property**, **and an increase in non-cash LTIP compensation expense and higher net income**, **expense**.

Net cash used in investing activities for the ~~three~~ six months ended ~~March 31, 2024~~ June 30, 2024 was ~~\$2.7 million~~ \$0.9 million, compared to net cash provided by investing activities of ~~\$3.1 million~~ \$65.1 million for the same period in 2023. During the 2024 period ~~we received less net proceeds from the sale of investment properties and more funds were used for capital expenditures on existing real estate investments and leasing commissions and we received no proceeds from the sale of investment properties.~~ commissions.

Net cash used in financing activities for the ~~three~~ six months ended ~~March 31, 2024~~ June 30, 2024 was ~~\$10.5 million~~ \$31.2 million, compared ~~\$19.3 million~~ \$103.4 million for the same period in 2023. During the 2024 period, ~~in addition to dividends paid to common and preferred stockholders as well as holders of OP Units and LTIP Units,~~ we had net borrowings on our Credit Facility. ~~Facility,~~ partially offset by the repayment of our notes payable.

-36-

[Table of Contents](#)

Non-GAAP Financial Measures

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of those measures to the most directly comparable GAAP financial measure.

-33-

[Table of Contents](#)

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Report.

Funds from Operations and Adjusted Funds from Operations

Funds from operations ~~attributable to common stockholders and noncontrolling interest~~ ("FFO") and adjusted funds from operations ~~attributable to common stockholders and noncontrolling interest~~ ("AFFO") are non-GAAP financial measures within the meaning of the rules of the SEC. The Company considers FFO and AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results.

In accordance with the National Association of Real Estate Investment Trusts' ("NAREIT") definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP Units and LTIP Units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company's operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include recurring acquisition and disposition costs, loss on the extinguishment of debt, recurring straight line deferred rental revenue, recurring stock-based compensation expense, recurring amortization of above and below market leases, recurring amortization of debt issuance costs, and other items.

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

-34- -37-

[Table of Contents](#)

A reconciliation of net income to FFO and AFFO for the three and six months ended March 31, 2024 June 30, 2024 and 2023 is as follows:

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
(unaudited, in thousands except per share and unit amounts)						
Net income	\$ 2,314	\$ 2,173				
(unaudited, in thousands except per share and unit amounts)						
Net (loss) income			\$ (1,952)	\$ 14,177	\$ 362	\$ 16,350
Less: Preferred stock dividends	(1,455)	(1,455)	(1,455)	(1,455)	(2,911)	(2,911)
Depreciation and amortization expense	14,024	14,861	13,969	14,774	27,992	29,635
Gain on sale of investment property	—	(485)				
FFO	\$ 14,883	\$ 15,094				
Loss (gain) on sale of investment properties			3,383	(12,786)	3,383	(13,271)
FFO attributable to common stockholders and noncontrolling interest			\$13,945	\$ 14,710	\$28,826	\$ 29,803
Amortization of above market leases, net	251	291	249	287	500	578
Straight line deferred rental revenue	(400)	(763)	(363)	(879)	(763)	(1,642)
Stock-based compensation expense	1,233	688	1,319	1,147	2,552	1,835
Amortization of debt issuance costs and other	562	601	563	601	1,125	1,202
Preacquisition expense	—	42	—	2	—	44
AFFO	\$ 16,529	\$ 15,953				
AFFO attributable to common stockholders and noncontrolling interest			\$15,713	\$ 15,868	\$32,240	\$ 31,820

Net income attributable to common stockholders per share – basic and diluted	\$ 0.01	\$ 0.01				
FFO per share and unit	\$ 0.21	\$ 0.22				
AFFO per share and unit	\$ 0.23	\$ 0.23				
Net (loss) income attributable to common stockholders per share – basic and diluted			\$ (0.05)	\$ 0.18	\$ (0.04)	\$ 0.19
FFO attributable to common stockholders and noncontrolling interest per share and unit			\$ 0.20	\$ 0.21	\$ 0.41	\$ 0.43
AFFO attributable to common stockholders and noncontrolling interest per share and unit			\$ 0.22	\$ 0.23	\$ 0.46	\$ 0.45
Weighted Average Shares and Units Outstanding – basic and diluted	70,757	69,830	70,982	70,434	70,844	70,119
Weighted Average Shares and Units Outstanding:						
Weighted Average Common Shares	65,573	65,525	65,588	65,544	65,580	65,534
Weighted Average OP Units	2,244	1,667	2,244	2,143	2,244	1,907
Weighted Average LTIP Units	2,940	2,638	3,150	2,747	3,020	2,678
Weighted Average Shares and Units Outstanding – basic and diluted	70,757	69,830	70,982	70,434	70,844	70,119

Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (EBITDAre and Adjusted EBITDAre)

The Company calculates EBITDAre in accordance with standards established by NAREIT and defines EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, and impairment loss, as applicable. The Company defines Adjusted EBITDAre as EBITDAre plus loss on extinguishment of debt, non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, preacquisition expense and other normalizing items. Management considers EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

-35- -38-

[Table of Contents](#)

A reconciliation of net income to EBITDAre and Adjusted EBITDAre for the three and six months ended March 31, 2024 June 30, 2024 and 2023 is as follows:

Three Months Ended March 31,		Three Months Ended June 30, Six Months Ended June 30,			
2024	2023	2024	2023	2024	2023

	(unaudited and in thousands)		
Net income	\$ 2,314	2,173	

		(unaudited and in thousands)					
Net (loss) income				\$ (1,952)	\$ 14,177	\$ 362	\$ 16,350
Interest expense	6,890	8,271		6,992	8,468	13,883	16,739
Depreciation and amortization expense	14,084	14,889		13,993	14,805	28,078	29,694
Gain on sale of investment property	—	(485)					
Loss (gain) on sale of investment properties				3,383	(12,786)	3,383	(13,271)
EBITDAre	\$ 23,288	\$ 24,848	\$ 22,416	\$ 24,664	\$ 45,706	\$ 49,512	
Stock-based compensation expense	1,233	688	1,319	1,147	2,552	1,835	
Amortization of above market leases, net	251	291	249	287	500	578	
Preacquisition expense	—	42	—	2	—	44	
Adjusted EBITDAre	\$ 24,772	\$ 25,869	\$ 23,984	\$ 26,100	\$ 48,758	\$ 51,969	

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Market risk includes risks that arise from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. In pursuing our business and investment objectives, we expect that the primary market risk to which we will be exposed is interest rate risk.

We may be exposed to the effects of interest rate changes primarily as a result of debt used to acquire healthcare facilities, including borrowings under the Credit Facility. The analysis below presents the sensitivity of the value of our variable rate financial obligations to selected changes in market interest rates. The range of changes chosen reflects our view of changes which are reasonably possible over a one-year period.

As of **March 31, 2024** **June 30, 2024**, we had **\$98.6 million** **\$105.0 million** of unhedged borrowings outstanding under the Revolver (before the netting of unamortized debt issuance costs) that bears interest at a variable rate. See “*Management’s Discussion and Analysis of Financial Condition and Results of Operation—Liquidity and Capital Resources*,” for a detailed discussion of our Credit Facility. At **March 31, 2024** **June 30, 2024**, SOFR on our outstanding floating-rate borrowings was **5.33%** **5.34%**. Assuming no increase in the amount of our variable interest rate debt, if SOFR increased 100 basis points, our cash flow would decrease by approximately **\$1.0** **\$1.1** million annually. Assuming no increase in the amount of our variable rate debt, if SOFR were reduced 100 basis points, our cash flow would increase by approximately **\$1.0 million** **\$1.1 million** annually.

Our interest rate risk management objectives are to limit the impact of interest rate changes on earnings and cash flows and to lower overall borrowing costs. To achieve our objectives, we may borrow at fixed rates or floating rates. See “*Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Hedging Instruments*,” for a description of our interest rate swaps.

We may enter into additional derivative financial instruments, including interest rate swaps and caps, in order to mitigate our interest rate risk on our future borrowings. We will not enter into derivative transactions for speculative purposes.

In addition to changes in interest rates, the value of our investments is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants/operators and borrowers, which may affect our ability to refinance our debt if necessary.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act that are designed to ensure that information required to be disclosed in our reports filed or submitted to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms, and that information is accumulated and communicated to management, including the principal executive and financial officer as appropriate, to allow timely decisions regarding required disclosures. Our principal executive officer and principal financial officer evaluated the effectiveness of

disclosure controls and procedures as of **March 31, 2024** **June 30, 2024** pursuant to Rule 13a-15(b) under the Exchange Act. Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this Report, the Company's disclosure controls and procedures were effective to ensure that information required to be included in our periodic SEC filings is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms.

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

Changes in Internal Control over Financial Reporting

No changes were made to our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on our financial condition or results of operations. From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. There can be no assurance that these matters that arise in the future, individually or in the aggregate, will not have a material adverse effect on our financial condition or results of operations in any future period.

Item 1A. Risk Factors

During the **three six** months ended **March 31, 2024** **June 30, 2024**, there were no material changes to the risk factors that were disclosed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 28, 2024.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

-37- -40-

[Table of Contents](#)

Item 6. Exhibits

(a) Exhibits

Exhibit No.	Description
-------------	-------------

3.1	Articles of Restatement of Global Medical REIT Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q as filed with the SEC on August 8, 2018).
3.2	Fourth Amended and Restated Bylaws of Global Medical REIT Inc., adopted as of December 7, 2022 (incorporated herein by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K as filed with the SEC on December 7, 2022).
4.1	Specimen of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-11/A as filed with the SEC on June 15, 2016).
4.2	Specimen of 7.50% Series A Cumulative Redeemable Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the SEC on September 14, 2017).
10.1†	Global Medical REIT Inc. 2016 Equity Incentive Plan (as amended through May 15, 2024) (incorporated herein by reference to Appendix A of Global Medical REIT Inc.'s Definitive Proxy Statement on Schedule 14A, as filed with the SEC on April 1, 2024).
31.1*	Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Principal Executive Officer and Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS *	Inline XBRL Instance Document
101.SCH *	Inline XBRL Taxonomy Schema
101.CAL *	Inline XBRL Taxonomy Calculation Linkbase
101.DEF *	Inline XBRL Taxonomy Definition Linkbase
101.LAB *	Inline XBRL Taxonomy Label Linkbase
101.PRE *	Inline XBRL Taxonomy Presentation Linkbase
104	Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)

* Filed herewith.

** Furnished herewith. Such certification shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

† Management contract or compensatory plan or arrangement.

-38- -41-

[Table of Contents](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GLOBAL MEDICAL REIT INC.

Date: May 8, 2024 August 7, 2024

By: /s/ Jeffrey M. Busch

Jeffrey M. Busch

Chief Executive Officer (Principal Executive Officer)

Date: May 8, 2024 August 7, 2024

By: /s/ Robert J. Kiernan

Robert J. Kiernan

Chief Financial Officer (Principal Financial and Accounting Officer)

-39- -42-

Exhibit 31.1

CERTIFICATIONS

I, Jeffrey M. Busch, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2024 June 30, 2024 of Global Medical REIT Inc. (the "registrant");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024 August 7, 2024

/s/ Jeffrey M. Busch

Jeffrey M. Busch, Chief Executive Officer
(Principal Executive Officer)

Exhibit 31.2

CERTIFICATIONS

I, Robert J. Kiernan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2024 June 30, 2024 of Global Medical REIT Inc. (the "registrant");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024 August 7, 2024

/s/ Robert J. Kiernan

Robert J. Kiernan, Chief Financial Officer
(Principal Financial and Accounting Officer)

Section 1350 Certification of Chief Executive Officer and Chief Financial Officer

In connection with the Quarterly Report on Form 10-Q of Global Medical REIT Inc. (the "Company") for the period ended **March 31, 2024** **June 30, 2024** as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jeffrey M. Busch, Chief Executive Officer of the Company and I, Robert J. Kiernan, Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: **May 8, 2024** **August 7, 2024**/s/ Jeffrey M. Busch

Jeffrey M. Busch, Chief Executive Officer
(Principal Executive Officer)

Date: **May 8, 2024** **August 7, 2024**/s/ Robert J. Kiernan

Robert J. Kiernan, Chief Financial Officer
(Principal Financial and Accounting Officer)

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.